

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/053057 A2

(51) International Patent Classification ⁷ :	C12N	CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
(21) International Application Number:	PCT/US2003/034563	
(22) International Filing Date:	31 October 2003 (31.10.2003)	
(25) Filing Language:	English	
(26) Publication Language:	English	(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
(30) Priority Data:	60/432,651 11 December 2002 (11.12.2002) US	
(71) Applicant:	3M INNOVATIVE PROPERTIES COMPANY [US/US]; 3M Center, Post Office Box 33427, Saint Paul, MN 55133-3427 (US).	
(72) Inventors:	GUPTA, Shalley K.; Post Office Box 33427, Saint Paul, MN 55133-3427 (US). GHOSH, Tarun K.; Post Office Box 33427, Saint Paul, MN 55133-3427 (US). FINK, Jason R.; Post Office Box 33427, Saint Paul, MN 55133-3427 (US).	
(74) Agents:	GRAM, Christopher D., et al.; Office of Intellectual Property Counsel, Post Office Box 33427, Saint Paul, MN 55133-3427 (US).	
(81) Designated States (national):	AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,	



WO 2004/053057 A2

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENE EXPRESSION SYSTEMS AND RECOMBINANT CELL LINES

(57) Abstract: The present invention provides gene expression systems useful for detecting agonists of Toll-like receptors. The gene expression systems include a nucleic acid sequence encoding a Toll-like receptor and a second nucleic acid sequence that encodes a reporter operably linked to an expression control sequence. The recombinant cell lines include a gene expression system according to the present invention.

GENE EXPRESSION SYSTEMS AND RECOMBINANT CELL LINES**Background of the Invention**

Cells of the immune system secrete a diverse set of compounds including
5 cytokines, chemokines, co-stimulatory markers, and defensins in response to an immunological challenge.

Certain compounds known as immune response modifiers ("IRMs") possess potent immunostimulating activity including but not limited to antiviral and antitumor activity. Certain IRMs effect their immunostimulatory activity by, e.g., inducing the production and 10 secretion of certain cytokines while inhibiting production and secretion of other cytokines. Certain IRMs are small organic molecules such as those disclosed in, for example, U.S. Patent Nos. 4,689,338; 4,929,624; 5,266,575; 5,268,376; 5,352,784; 5,389,640; 5,482,936; 5,494,916; 6,110,929; 6,194,425; 4,988,815; 5,175,296; 5,367,076; 5,395,937; 5,693,811; 5,741,908; 5,238,944; 5,939,090; 6,245,776; 6,039,969; 6,083,969; 6,245,776; 6,331,539; 15 and 6,376,669; and PCT Publications WO 00/76505; WO 00/76518; WO 02/46188, WO 02/46189; WO 02/46190; WO 02/46191; WO 02/46192; WO 02/46193; and WO 02/46194.

Additional small molecule IRMs include purine derivatives (such as those described in U.S. Patent Nos. 6,376,50 and 6,028,076), small heterocyclic compounds 20 (such as those described in U.S. Patent No. 6,329,381), and amide derivatives (such as those described in U.S. Patent No. 6,069,149).

Other IRMs include large biological molecules such as oligonucleotide sequences. Some IRM oligonucleotide sequences contain cytosine-guanine dinucleotides (CpG) and are described, for example, in U.S. Patent Nos. 6,1994,388; 6,207,646; 6,239,116; 25 6,339,068; and 6,406,705. Other IRM nucleotide sequences lack CpG and are described, for example, in International Patent Publication No. WO 00/75304.

Some of these IRMs induce cellular responses (e.g., the production and/or secretion of cytokines, chemokines, etc.) through one or more Toll-like receptors (TLRs). For example, certain small organic molecule IRMs are agonists of one or more of TLR-1, 30 TLR-2, TLR-4, TLR-6, TLR-7, and TLR-8. Additionally, CpG has been reported to act through TLR 9.

In certain cells of the immune system, TLR activation can be associated with activation of the transcription factor NF- κ B. NF- κ B activation is associated with certain cellular responses to an immunological challenge, such as the production and secretion of pro-inflammatory cytokines such as TNF- α , IL-1, IL-6, IL-8, IL-10, IL-12, MIP-1, and MCP-1. IRM induction of such cellular responses can be demonstrated by measuring activation of the transcription factor NF- κ B in response to exposing a cell to an IRM compound (See, e.g., Chuang *et al.*, *Journ. of Leuk. Biol.*, vol. 71, pp. 538-544 (2002), and Hemmi *et al.*, *Nature Immunology*, vol. 3(2), pp. 196-200 (2002)). Thus, NF- κ B activation can be used as a reporter of TLR activation. However, the extent of NF- κ B activation does not necessarily correlate with the extent of the downstream cellular response. This is so because the downstream cellular response may be modulated by one or more additional factors.

Summary of the Invention

The present invention provides an expression system that includes a first nucleic acid sequence that encodes a Toll-like receptor operably linked to a first expression control sequence; and a second nucleic acid sequence that encodes a reporter that (a) generates a detectable signal when the reporter is expressed and the cell is exposed to conditions effective for generating the detectable signal, and (b) is operably linked to a second expression control sequence that comprises a cytokine promoter, a chemokine promoter, a co-stimulatory marker promoter, or a defensin promoter. In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are included on a single vector. In other embodiments, the first nucleic acid sequence and the second nucleic acid sequence are located on separate vectors.

In another aspect, the present invention provides a recombinant cell line that includes a host cell transfected with an expression system. In some embodiments, the expression system is contained within a single vector. In other embodiments, the expression system is contained among two or more vectors so that the host cell is co-transfected with all of the vectors of the expression system to obtain the recombinant cell line. In one embodiment, the host cell is a Namalwa cell.

In another aspect, the present invention provides a TLR agonist identified using either an expression system or a recombinant cell line according to the present invention.

In yet another aspect, the present invention provides pharmaceutical compositions including a TLR agonist identified using either an expression system or a recombinant cell line according to the present invention.

Various other features and advantages of the present invention should become
5 readily apparent with reference to the following detailed description, examples, and appended claims. In several places throughout the specification, guidance is provided through lists of examples. In each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive list.

10

Detailed Description of Illustrative Embodiments of the Invention

The present invention provides gene expression systems and recombinant cell lines that may be useful for detecting TLR activation based on detecting induction of a downstream cellular response to TLR activation (e.g., production or secretion of one or more immune system compounds such as cytokines or co-stimulatory markers) rather than NF- κ B activation. In some cases, the cellular response may be mediated by NF- κ B, but in other cases the cellular response may be NF- κ B-independent. Thus, the present invention provides gene expression systems and recombinant cell lines that may be useful for detecting a broader range of TLR activation than is possible by monitoring NF- κ B activation. This may provide an ability to identify certain TLR agonists that would not be detected using an assay based on NF- κ B activation. The gene expression systems and recombinant cell lines of the present invention also may provide a more relevant indication of the quantitative character of a particular cellular response to TLR activation by a particular TLR agonist.
15
20

In some cases, a gene expression system or recombinant cell line according to the present invention may be useful for detecting TLR activation that is not accompanied by NF- κ B activation. Accordingly, the gene expression system and recombinant cell line may be employed to identify TLR agonists that do not necessarily also activate NF- κ B. Such TLR agonists may be useful for treatment or prevention of certain conditions in which the production and secretion of pro-inflammatory cytokines such as those induced by NF- κ B activation may be undesirable.
25
30

For purposes of this invention, the following terms shall have the meanings set forth.

“Activation” refers to modifying the indicated protein so that the protein provides a biological function. For example, TLR activation refers to modifying a TLR - for example, a conformational modification such as in response to exposure of the TLR to an agonist - so that the TLR is capable of inducing the production and secretion of certain cytokines.

“Agonist” refers to a compound that can combine with a receptor (e.g., a TLR) to produce a cellular response. An agonist may be a ligand that directly binds to the receptor. Alternatively, an agonist may combine with a receptor indirectly by, e.g., (a) forming a complex with another molecule that directly binds to the receptor, or (b) otherwise results in the modification of another compound so that the other compound directly binds to the receptor. An agonist may be referred to as an agonist of a particular TLR (e.g., a TLR6 agonist).

“Amino acid sequence” refers to a particular ordered sequence of amino acids, whether naturally occurring or engineered.

“Co-transfect” and variations thereof refer to transfecting a host cell with more than one vector. A host cell may be co-transfected by transfecting with two or more vectors one at a time or in any convenient combination of vectors, including simultaneous transfection with all vectors.

“Express” and variations thereof refer to the ability of a cell to transcribe a structural gene to mRNA, then translate the mRNA to synthesize a protein that provides a detectable biological or biochemical function. “Expressible” refers to the ability of a particular nucleic acid sequence to be expressed by a cell that contains the nucleic acid sequence.

“Immune system compound” refers to any compound that is produced or secreted by cells of the immune system in response to an immunological challenge. Immune system compounds include but are not limited to cytokines, chemokines, co-stimulatory markers, and defensins.

“IRM compound” refers to a compound that alters the level of one or more immune system compounds when administered to an IRM-responsive cell. Representative IRM compounds include the small organic molecules, purine derivatives, small heterocyclic compounds, amide derivatives, and oligonucleotide sequences described above.

“Nucleic acid sequence” refers generally to a region of DNA that has a definable function such as (a) encoding a peptide, polypeptide, or protein or (b) controlling expression of a nucleic acid sequence that encodes a peptide, polypeptide, or protein. For example, a nucleic acid sequence that encodes TLR6 refers generically to any sequence of 5 nucleotides that encodes a TLR6 protein, without regard to (a) the species source of the nucleic acid sequence, (b) specific nucleotide sequence variants, or (c) whether such nucleotide sequence variants are naturally occurring or engineered.

“Nucleotide sequence” refers to a particular ordered sequence of nucleotide bases, whether naturally occurring or engineered.

10 It has been found that induction of certain secreted proteins or polypeptides can be useful as reporters of TLR activation. For example, IFN- α is a cytokine secreted by such immune system cells as T lymphocytes, macrophages, plasmacytoid monocytes, dendritic cells, and natural killer cells. IFN- α is involved in regulating a host's innate and adaptive immune responses to an immunological challenge, perhaps by providing a link between 15 the two responses [Brassard *et al.*, *Journal of Leukocyte Biology* 71: 565-581 (2002)]. The innate immune response can include the cell-mediated response of natural killer (NK) cells to a non-self (e.g., neoplastic) or foreign (e.g., viral) antigen. IFN- α also may indirectly regulate the balance between Th1 and Th2 cell populations and, therefore, the innate and adaptive immune responses. Moreover, induction of IFN- α is independent of NF- κ B 20 activation.

25 Additionally, the production and secretion of NF- κ B-dependent cytokines can be useful as reporters of cellular responses resulting from immunological challenge. Detection and measurement of such cytokines may provide comparative qualitative data regarding a cell's response to immunological challenge that is more relevant to an investigator than NF- κ B activation data.

Thus, in certain embodiments, the present invention relates to recombinant cell lines and gene expression systems designed to assist detecting induction of immune system compounds and identification of compounds that induce expression of immune system compounds through TLRs.

30 Parts of the following description are provided in the context of IFN- α induction and detection. However, many of the features of the embodiments described below also may be realized using expression systems and recombinant cell lines designed to

specifically detect or induce other immune system compounds. Thus, expression systems and recombinant cell lines designed to specifically detect or induce immune system compounds other than IFN- α are explicitly included in the scope of the present invention.

The present invention provides a recombinant cell line capable of inducing gene expression from an expression control sequence of a gene that encodes an immune system compound (e.g., IFN- α) in response to TLR activation. In some embodiments, for example, cells of the recombinant cell line, when exposed to a TLR agonist, can induce expression from an IFN- α promoter to a greater extent than cells of the corresponding untransfected cell line. Cells of the untransfected cell lines may substantially lack a functional level of TLR expression (i.e., untransfected cells may not detectably induce expression from the IFN- α promoter in response to exposure to a TLR agonist). Alternatively, cells of the untransfected cell line may exhibit a baseline level of background TLR function, but the baseline level is less than the level of TLR function observed in cells of the corresponding recombinant (i.e., transfected) cell line.

Cells of the recombinant cell lines include a first nucleic acid sequence that encodes a TLR operably linked to an expression control sequence. The cells also include a second nucleic acid sequence that encodes a reporter capable of generating a detectable signal when it is expressed in the recombinant cell under conditions suitable for generating the detectable signal. The reporter is linked to a second expression control sequence that is capable of being induced by activation of the TLR encoded by the first nucleic acid sequence.

The TLR encoded by the first nucleic acid sequence may be any TLR. Ten different human TLRs have been identified, cloned, and sequenced. TLRs also are known to exist in other mammals including, for example, mice and chimpanzees. The nucleotide sequences of the ten human TLRs and many non-human TLRs are known, have been published, and are readily accessible from various sequence databases including GenBank. The first nucleic acid sequence may include the nucleotide sequence of any one of the TLRs, whether human or non-human. In one embodiment, the TLR is human TLR6; in another embodiment, the TLR is human TLR7. Alternatively, the first nucleic acid may encode any one of the ten human TLRs, any non-human TLR, or any combination of two or more TLRs that may be desirable for a particular construct.

The first nucleic acid sequence can include a nucleotide sequence that differs from a specific published nucleotide sequence for the TLR encoded by the first nucleic acid sequence. For example, the first nucleic acid sequence can contain one or more substitutions (compared to a published TLR nucleotide sequence) that do not alter the 5 amino acid sequence of the TLR protein expressed from the first nucleic acid sequence. Such a substitution may be termed a degenerate substitution. Nucleotide sequences containing one or more degenerate substitutions compared to a known TLR nucleotide sequence are explicitly included within the scope of nucleotide sequences suitable for use within the first nucleic acid sequence.

As another example, certain nucleotide substitutions may alter the amino acid 10 sequence of the TLR protein. For certain amino acid substitutions, however, the chemical properties of the protein having the altered amino acid sequence are similar to the chemical properties of the protein having the native amino acid sequence. Amino acids may be divided into four groups based on the chemical characteristics of the amino acid 15 side groups: neutral, non-polar amino acids include glycine, alanine, valine, isoleucine, leucine, phenylalanine, proline, and methionine; neutral, polar amino acids include serine, threonine, tyrosine, tryptophan, asparagine, glutamine, and cysteine; acidic amino acids include aspartic acid and glutamic acid; and basic amino acids include lysine, arginine, and histidine. Substitution of one amino acid for another amino acid within the same 20 group may have little or no functional effect on the resulting protein because of the similarity of the chemical characteristics of the amino acids involved in the substitution. Such amino acid substitutions may be termed a conservative amino acid substitution. Nucleotide sequences that, when compared to a known TLR nucleotide sequence, generate 25 one or more conservative amino acid substitutions are explicitly included within the scope of nucleotide sequences suitable for use within the first nucleic acid sequence.

The nucleic acid that encodes a TLR may be cloned into an expression vector so that it is under the expression control of its own promoter, a homologous TLR promoter, or any heterologous promoter inducible in an appropriate host cell. For example, in certain embodiments, the TLR6 structural gene may be cloned into the commercially 30 available mammalian expression vector pCI-neo. In this case, the TLR6 structural gene may be cloned into the vector's cloning region using the NheI and MluI restrictions sites. In such an embodiment, after transfection of the vector into a mammalian cell, the TLR6

structural gene is under the transcriptional control of the vector's CMV enhancer/promoter region.

The second nucleic acid sequence encodes a reporter that is capable of generating a detectable signal when expressed in a host cell under conditions appropriate for generating the desired detectable signal. A wide variety of suitable reporter systems are known. For example, luciferase gene expression may generate a detectable luminescent signal under appropriate conditions. As another example, β -galactosidase expression can generate a detectable color change under appropriate conditions. As yet another example, production and secretion of an immune system compound may be detected by an enzyme-linked immunosorbent assay (ELISA). These and other reporter systems are known and assays for generating the detectable signals are commercially available.

The second nucleic acid sequence is operably linked to a second expression control sequence that includes a promoter sequence selected to be inducible by activation of the TLR encoded by the first nucleic acid sequence. Thus, expression and activation of the TLR encoded by the first nucleic acid sequence will induce gene expression from the second expression control sequence, thereby causing expression of the reporter, which may be detected by performing an assay designed to detect expression of the reporter. The second expression control sequence may include any suitable nucleotide sequence that can induce expression (e.g., a promoter) of a structural gene upon activation of the TLR encoded by the first nucleic acid sequence. Nucleotide sequences suitable for use as second expression control sequences include promoter sequences of TLR-inducible genes including but not limited to genes encoding cytokines, chemokines, co-stimulatory markers, and defensins. In certain embodiments, the second expression control sequence can include an IFN- α 1 promoter. When the reporter system being employed to detect TLR activation includes detecting production and secretion of an immune system compound with an appropriate ELISA assay, the second expression control sequence may include the promoter of the gene encoding the immune system compounds being expressed and detected as the reporter. However, in certain embodiments, it may be desirable to express the immune system compound from a heterologous promoter.

The first nucleic acid sequence and the second nucleic acid sequence may be contained within a single vector. Alternatively, the first nucleic acid sequence and the second nucleic acid sequence may be on separate vectors and co-transfected into a suitable

host cell. In certain embodiments, for example, the first nucleic acid sequence may be cloned into the pCI-neo vector as described above, while the second nucleic acid sequence can be cloned into a reporter vector. One example of a commercially available reporter vector is the pGL3-Enhancer vector, which includes a luciferase reporter gene downstream of a cloning site for cloning a promoter sequence of interest. In some embodiments, the promoter of a TLR-inducible immune system compound may be cloned into the pGL3-Enhancer cloning site. In one such embodiment, the IFN- α promoter may be cloned into the pGL3-Enhancer cloning site.

Suitable host cells include any transfectable cells capable of expressing exogenous mammalian genes. In some embodiments, the host cells may be mammalian cells such as human cells or mouse cells. For example, suitable host cells include human cells or descendants of a human cell including but not limited to Namalwa cells or HEK293 cells. Alternatively, the host cells may be mouse cells or descendants of a mouse cell including but not limited to RAW 264.7 cells.

In one embodiment, the host cells include Namalwa cells. Namalwa cells have certain characteristics that may be particularly desirable for certain embodiments of the present invention. For example, Namalwa cells can include an expressible chromosomal IFN- α gene locus. Thus, upon appropriate stimulation (e.g., viral infection), Namalwa cells can be induced to produce and secrete IFN- α from the chromosomal IFN- α gene locus. However, Namalwa cells do not naturally express certain TLRs (e.g., TLR6, TLR7, or TLR9). Certain agonists of such TLRs have been shown to induce IFN- α expression in other cell types (e.g., PMBCs), but may not induce IFN- α expression in Namalwa cells unless a functional level of TLR expression is provided.

Namalwa cells transfected with an expression system according to the present invention may be capable of expressing a functional level of the TLR provided by the expression system. Thus, Namalwa cells transfected with an expression system according to certain embodiments of the present invention may inducibly express IFN- α as a result of activating the cloned TLR (e.g., by exposure of the transfected Namalwa cells to an agonist). Thus, certain transfected cell lines of the present invention provide an ability to detect a TLR agonist by detecting TLR-mediated IFN- α expression by Namalwa cells. Such IFN- α expression may occur from the chromosomal IFN- α gene or from an IFN- α promoter cloned into the reporter vector.

Namalwa cells transfected with an expression system according to certain embodiments of the present invention can provide alternative means of detecting TLR expression. First, transfected Namalwa cells may generate a detectable signal as a result of expressing the reporter from the second expression control sequence, which may or may not include an IFN- α promoter (see Table 2). Second, transfected Namalwa cells may produce and secrete IFN- α from the chromosomal IFN- α gene locus. A transfected Namalwa cell line according to the present invention may be used to screen compounds in order to identify those compounds that induce TLR expression, i.e., TLR agonists.

Therefore, the present invention also provides TLR agonist compounds identified using an expression system or a recombinant cell line according to certain embodiments of the present invention. As described above, the expression systems and recombinant cell lines may provide the ability to identify TLR activation that may not be detectable using previously known TLR activation assays. A compound that induces TLR activity detectable by using a gene expression system or a recombinant cell line according to the present invention may be considered a TLR agonist. Such TLR agonists may include chemical structures similar in certain respects to the chemical structures of known IRM compounds. Alternatively, a gene expression system or a recombinant cell line according to the present invention may provide a tool for the screening (e.g., high throughput screening) chemically diverse compounds that may lead to the discovery of new TLR agonists, some of which may contain new chemical core structures capable of activating TLRs.

The present invention also provides pharmaceutical compositions containing a TLR agonist identified using an expression system or a recombinant cell line according to the present invention, or a pharmaceutically acceptable salt thereof, in an amount effective for inducing a TLR-mediated cellular response.

Examples

The following examples have been selected merely to further illustrate features, advantages, and other details of the invention. It is to be expressly understood, however, that while the examples serve this purpose, the particular materials and amounts used as well as other conditions and details are not to be construed in a matter that would unduly limit the scope of this invention.

Construction of vectors

The vector pIFN- α 1-luc was constructed by inserting BglII sites at both ends of the human IFN- α 1 promoter (SEQ ID NO:21). The BglII sites were inserted into the IFN- α 1 promoter and the sequence was amplified using the primer pair of SEQ ID NO:22 and SEQ ID NO:23. The amplified IFN- α 1 promoter was cloned into the pGL3-Enhancing vector (Promega Corp., Madison, WI) at its BglII site.

The vector pCI-TLR6 was constructed by inserting SEQ ID NO:11 (GenBank Accession No. NM 006068), which includes the human TLR6 coding sequence, into the pCI-neo mammalian expression vector (Promega Corp.) at the vector's NheI and MluI restriction sites.

Transfections

Unless otherwise indicated, all incubations were performed at 37°C with 5% CO₂ at 98% humidity.

Culture medium was prepared from complete RPMI 1640 medium (BioSource International, Inc., Camarillo, CA). Fetal bovine serum (Atlas Biologicals, Inc., Ft. Collins, CO) was added to a final concentration of 7.5% (vol/vol); L-glutamine (BioSource International, Inc.) was added to 5 mM; and sodium pyruvate (BioSource International, Inc.) was added to 1 mM.

Burkitt's Lymphoma lymphoblastoid Namalwa cells (ATCC Accession No. CRL-1432) were grown by incubation in culture medium overnight. Cells were harvested by centrifugation in a tabletop centrifuge (1200 RPM for 5 minutes), and then resuspended in phosphate buffered sucrose to a concentration of 1.3×10^7 cells per milliliter.

For each transfection, a 750 μ L aliquot of the cell suspension was placed in an electroporation cuvette with 4 mm gaps. 10 μ g of the pIFN- α 1-luc vector and 10 μ g of the pCI-TLR6 vector were added to the electroporation cuvette. The cell and vector mixtures were incubated at room temperature for 5 minutes. The cells were electroporated using a BioRad Gene Pulser (BioRad Laboratories, Hercules, CA) set to at 500 μ F capacitance and 0.27 volts, then incubated at room temperature for 5 minutes.

The electroporated cells were suspended in 10 mLs of culture medium and incubated overnight. Dead cells and debris were removed after 24 hours using a MACS

Dead Cell Removal kit (Miltenyi Biotec, Auburn, CA). Cells were resuspended in 10 mLs of culture medium and incubated for an additional 24 hours.

Transfected cells were selected by adding G418 (Promega Corp., Madison, WI) to a final concentration of 1 mg/mL and incubating the cells for seven days.

5

Assays

The selected transfected cells were counted and resuspended to a concentration of 1×10^6 cell per mL in culture medium. 100 μ L aliquots of cells were placed in the wells of a white-walled, white-bottomed 96-well plate (Corning, Inc. Corning, NY). 1.0 μ L of an IRM compound from Table 1 (prepared at 1 mM in 100% DMSO) was added to some cell aliquots so that the final concentration of IRM compound was 10 μ M. As a positive control, some cell aliquots were incubated with Sendai virus instead of IRM compound. As a negative control, some cell aliquots were incubated with DMSO without IRM compound. In all cases, the cells were incubated for 18 hours.

15

Table 1 - IRM Compounds

Compound	Chemical Name	Citation
IRM 1	4-amino-2-ethoxymethyl- α,α -dimethyl-6,7,8,9-tetrahydro-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinoline-1-ethanol	U.S. 5,352,784 Example 91
IRM 2	4-amino- α,α ,2-trimethyl-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinoline-1-ethanol	U.S. 5,266,575 Example C1
IRM 3	N-[4-(4-amino-2-butyl-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinolin-1-yl)butyl]methanesulfonamide	U.S. 6,331,539 Example 6
IRM 4	1-{2-[3-(3-pyridyl)propoxy]ethyl}-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinolin-4-amine	WO 02/46193 Example 33
IRM 5	2-butyl-1-(2-methylpropyl)-1 <i>H</i> -imidazo[4,5- <i>c</i>][1,5]naphthyridin-4-amine	U.S. 6,194,425 Example 39
IRM 6	2-butyl-6,7,8,9-tetrahydro-1-(2-methylpropyl)-1 <i>H</i> -imidazo[4,5- <i>c</i>][1,5]naphthyridin-4-amine	U.S. 6,194,425 Example 40
IRM 7	N ³ -{4-[4-amino-2-(2-methoxyethyl)-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinolin-1-yl]butyl}-6-(1 <i>H</i> -1-pyrrolyl)nicotinamide	U.S. 6,451,810 Example 60
IRM 8	2-ethyl-1-[5-(methylsulfonyl)pentyl]-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinolin-4-amine	WO 02/46192 Example 13

The plates were equilibrated to room temperature before 1 volume of reconstituted LucLight Plus (Packard Instruments, Meriden, CT) was added to each aliquot of cells. Each well of the plate was read on an L JL Analyst (L JL Biosystems, Inc., Sunnyvale, CA) set with a 5 minute dark adapt. Data from a representative experiment are shown in Table 5 2. The data are expressed as the fold increase in luciferase induction off of the IFN- α 1 promoter in cell aliquots incubated with the indicated stimulant compared to the negative control in which the cell aliquots were incubated with only DMSO.

10 **Table 2 - TLR Expression by pIFN- α 1-luc/pCI-TLR6 Co-Transfected Namalwa cells**

<u>Stimulant</u>	<u>Fold Increase in Luciferase Induction</u>
IRM1	3.6
IRM2	2.7
IRM3	2.6
IRM4	4.0
IRM5	3.2
IRM6	2.9
IRM7	3.2
IRM8	2.3
Sendai virus	2.7

The complete disclosures of the patents, patent documents and publications cited herein are incorporated by reference in their entirety as if each were individually 15 incorporated. In case of conflict, the present specification, including definitions, shall control.

Various modifications and alterations to this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention. Illustrative embodiments and examples are provided as examples only and are not 20 intended to limit the scope of the present invention. The scope of the invention is limited only by the claims set forth as follows.

What is Claimed is:

1. An expression system comprising:
 - a first nucleic acid sequence that encodes a Toll-like receptor operably linked to a first expression control sequence; and
 - 5 a second nucleic acid sequence that encodes a reporter that (a) generates a detectable signal when the reporter is expressed and the cell is exposed to conditions effective for generating the detectable signal, and (b) is operably linked to a second expression control sequence that comprises a cytokine promoter, a chemokine promoter, a co-stimulatory marker promoter, or a defensin promoter.
- 10 2. The expression system of claim 1 wherein the second expression control sequence comprises an IFN- α promoter.
- 15 3. The expression system of claim 1 wherein the first nucleic acid sequence comprises the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, or a degenerate variant of any of the foregoing.
- 20 4. The expression system of claim 1 wherein the first nucleic acid sequence comprises a nucleotide sequence that encodes a polypeptide having the sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, or any one of the foregoing sequences with one or more conservative amino acid substitutions.
- 25 5. The expression system of claim 1 wherein the detectable signal comprises luciferase activity or β -galactosidase activity.
6. The expression system of claim 1 wherein a first vector comprises the first nucleic acid sequence and a second vector comprises the second nucleic acid sequence.
- 30 7. A vector comprising the expression system of claim 1.

8. A TLR agonist identified using the expression system of claim 1.
9. A pharmaceutical composition comprising the TLR agonist of claim 8, or a pharmaceutically acceptable salt thereof.
5
10. A cultured cell comprising the expression system of claim 1.
11. The cultured cell of claim 10 wherein the cell is a mammalian cell or a descendent of a mammalian cell.
10
12. The culture cell of claim 11 wherein the cell is a human cell or a descendent of a human cell.
13. The cultured cell of claim 10 further comprising an expressible nucleic acid sequence that encodes IFN- α operably linked to a third expression control sequence.
15
14. The cultured cell of claim 13 wherein the expressible nucleic acid sequence that encodes IFN- α is located on a chromosome of the cultured cell.
- 20 15. The cultured cell of claim 14 wherein the cultured cell is a Namalwa cell.
16. The cultured cell of claim 13 wherein the expressible nucleic acid sequence that encodes IFN- α is located on an extrachromosomal vector.
- 25 17. A TLR agonist identified using the cultured cell of claim 10.
18. A pharmaceutical composition comprising the TLR agonist of claim 17, or a pharmaceutically acceptable salt thereof.

58182US002.ST25.txt
SEQUENCE LISTING

<110> Gupta, Shalley K.
Ghosh, Tarun K.
Fink, Jason R.

<120> Gene Expression Systems and Recombinant Cell Lines

<130> 58182W0003

<160> 23

<170> PatentIn version 3.1

<210> 1

<211> 2832

<212> DNA

<213> Homo sapiens

<400> 1
acagactgcc aaatggaaca gacaaggcagg ttgtcttgc ttaaagaaaa tgagatatga 60
gtcagttact cccggaggca atgctgctgt tcagctcttgc tgttttgtg gccagggtct 120
tcataaacac taataggggt accaggccct cttccttgc agaagaaatc aggataacaa 180
aggatatattg ggcaccccta caaaaggaat ctgtatctgt atcaagatga tctgaagaac 240
agcttctacc ttttaggaatg tctagtgttc caaaatgact agcatcttcc attttgccat 300
tatcttcatg ttaatacttc agatcagaat acaattatct gaagaaatgt aatttttagt 360
tgataggtca aaaaacggtc tcatccacgt tcctaaagac ctatcccaga aaacaacaat 420
cttaaatata tcgcaaaatt atatatctga gctttggact tctgacatct tatcactgtc 480
aaaactgagg attttgataa tttctcataa tagaatccag tatcttgcata tcagtgttt 540
caaattcaac caggaattgg aatacttggc tttgtccac aacaagttgg tgaagatttc 600
ttgccaccct actgtgaacc tcaagcactt ggacctgtca ttatgcatt ttgatgccct 660
gcctatatgc aaagagtttgc gcaatatgtc tcaactaaaa ttctgggt tgagcaccac 720
acacttagaa aaatctatgt tgctgccaat tgctcatttgc aatatcagca aggtcttgc 780
ggcttagga gagacttatg gggaaaaaga agaccctgag ggccttcaag actttAACAC 840
tgagagtctg cacattgtgt tccccacaaa caaagaattc cattttatggatgtgtc 900
agtcaagact gtagcaaatc tggaaactatc taatatcaaa tgtgtgttag aagataacaa 960
atgttcttac ttccctaagta ttctggcgaa acttcaaaca aatccaaatgt tatcaagtct 1020
taccttaaac aacattgaaa caacttggaa ttcttcattt aggatcctcc agctggtttgc 1080
gcatacaact gtatggatt tctcaatttc aaacgtgaag ctacagggtc agctggactt 1140
cagagattt gattattctg gcacttcctt gaaggcatttgc tctatacacc aagttgtc 1200
cgatgtgttc gggtttccgc aaagttatctt ctatgaaatc ttctcataa tgaacatcaa 1260
aaatttcaca gtgtctggta cacgtatggt ccacatgctt tgccatcca aaatttagccc 1320

58182US002.ST25.txt

gttcctgcat ttggattttt ccaataatct cttaacagac acggttttg aaaattgtgg	1380
gcaccttact gagttggaga cacttatttt acaaatgaat caataaaag aactttcaaa	1440
aatagctgaa atgactcac acatgaagtc tctgcaacaa ttggatatta gccagaattc	1500
tgttagctat gatgaaaaga aaggagactg ttcttggact aaaagtttat taagttaaa	1560
tatgtcttca aatatactta ctgacactat ttccagatgt ttaccccca ggatcaaggt	1620
acttgatctt cacagcaata aaataaagag cattcctaaa caagtcgtaa aactggaagc	1680
tttgcagaa ctcaatgtt cttcaattc tttaactgac cttcctggat gtggcagctt	1740
tagcagcctt tctgtattga tcattgatca caattcagtt tcccacccat cagctgattt	1800
cttccagagc tgccagaaga tgaggtcaat aaaagcaggg gacaatccat tccaatgtac	1860
ctgtgagcta ggagaatttgc taaaaat agaccaagta tcaagtgaag tgttagaggg	1920
ctggcctgat tcttataagt gtgactaccc ggaaagttat agaggaaccc tactaaagga	1980
ctttcacatg tctgaattat cctgcaacat aactctgctg atcgtcacca tcgttgccac	2040
catgctggtg ttggctgtga ctgtgacctc cctctgcatt tacttggatc tgccctggta	2100
tctcaggatg gtgtgccagt ggacccagac ccggcgcagg gccaggaaca tacccttaga	2160
agaactccaa agaaatctcc agtttcatgc atttatttca tatagtggc acgattctt	2220
ctgggtgaag aatgaattat tgccaaacct agagaaagaa ggtatgcaga tttgccttca	2280
tgagagaaac tttgttcctg gcaagagcat tgtggaaaat atcatcacct gcattgagaa	2340
gagttacaag tccatcttgc tttgtctcc caactttgtc cagagtgaat ggtgccatta	2400
tgaactctac tttgcccattt acaatctctt tcatgaagga tctaatacgat taatcctgat	2460
cttgctggaa cccattccgc agtactccat tccttagcgt tatcacaagc tcaaaagtct	2520
catggccagg aggacttattt tgaaatggcc caaggaaaag agcaaacgtg gccttttttgc	2580
ggctaactta agggcagcca ttaatattaa gctgacagag caagcaaaga aatagattac	2640
acatcaagtgc aaaaatatttgc tccctgttga tattgctgct tttggaaattt ccaacaatgat	2700
ctttatatttgc catcagcata gatgtaaaca caattgtgag tgtatgtatgtt aggtaaaaat	2760
atataccttc gggtcgcagt tcaccatttgc tatgtggat taaaaattaa tgaaatgata	2820
taactttgtat tt	2832

<210> 2
 <211> 786
 <212> PRT
 <213> Homo sapiens

<400> 2

Met Thr Ser Ile Phe His Phe Ala Ile Ile Phe Met Leu Ile Leu Gln
 1 5 10 15

58182US002.ST25.txt

Ile Arg Ile Gln Leu Ser Glu Glu Ser Glu Phe Leu Val Asp Arg Ser
20 25 30

Lys Asn Gly Leu Ile His Val Pro Lys Asp Leu Ser Gln Lys Thr Thr
35 40 45

Ile Leu Asn Ile Ser Gln Asn Tyr Ile Ser Glu Leu Trp Thr Ser Asp
50 55 60

Ile Leu Ser Leu Ser Lys Leu Arg Ile Leu Ile Ile Ser His Asn Arg
65 70 75 80

Ile Gln Tyr Leu Asp Ile Ser Val Phe Lys Phe Asn Gln Glu Leu Glu
85 90 95

Tyr Leu Asp Leu Ser His Asn Lys Leu Val Lys Ile Ser Cys His Pro
100 105 110

Thr Val Asn Leu Lys His Leu Asp Leu Ser Phe Asn Ala Phe Asp Ala
115 120 125

Leu Pro Ile Cys Lys Glu Phe Gly Asn Met Ser Gln Leu Lys Phe Leu
130 135 140

Gly Leu Ser Thr Thr His Leu Glu Lys Ser Ser Val Leu Pro Ile Ala
145 150 155 160

His Leu Asn Ile Ser Lys Val Leu Leu Val Leu Gly Glu Thr Tyr Gly
165 170 175

Glu Lys Glu Asp Pro Glu Gly Leu Gln Asp Phe Asn Thr Glu Ser Leu
180 185 190

His Ile Val Phe Pro Thr Asn Lys Glu Phe His Phe Ile Leu Asp Val
195 200 205

Ser Val Lys Thr Val Ala Asn Leu Glu Leu Ser Asn Ile Lys Cys Val
210 215 220

Leu Glu Asp Asn Lys Cys Ser Tyr Phe Leu Ser Ile Leu Ala Lys Leu
225 230 235 240

Gln Thr Asn Pro Lys Leu Ser Ser Leu Thr Leu Asn Asn Ile Glu Thr
245 250 255

Thr Trp Asn Ser Phe Ile Arg Ile Leu Gln Leu Val Trp His Thr Thr
Page 3

58182US002.ST25.txt
260 265 270

Val Trp Tyr Phe Ser Ile Ser Asn Val Lys Leu Gln Gly Gln Leu Asp
275 280 285

Phe Arg Asp Phe Asp Tyr Ser Gly Thr Ser Leu Lys Ala Leu Ser Ile
290 295 300

His Gln Val Val Ser Asp Val Phe Gly Phe Pro Gln Ser Tyr Ile Tyr
305 310 315 320

Glu Ile Phe Ser Asn Met Asn Ile Lys Asn Phe Thr Val Ser Gly Thr
325 330 335

Arg Met Val His Met Leu Cys Pro Ser Lys Ile Ser Pro Phe Leu His
340 345 350

Leu Asp Phe Ser Asn Asn Leu Leu Thr Asp Thr Val Phe Glu Asn Cys
355 360 365

Gly His Leu Thr Glu Leu Glu Thr Leu Ile Leu Gln Met Asn Gln Leu
370 375 380

Lys Glu Leu Ser Lys Ile Ala Glu Met Thr Thr Gln Met Lys Ser Leu
385 390 395 400

Gln Gln Leu Asp Ile Ser Gln Asn Ser Val Ser Tyr Asp Glu Lys Lys
405 410 415

Gly Asp Cys Ser Trp Thr Lys Ser Leu Leu Ser Leu Asn Met Ser Ser
420 425 430

Asn Ile Leu Thr Asp Thr Ile Phe Arg Cys Leu Pro Pro Arg Ile Lys
435 440 445

Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser Ile Pro Lys Gln Val
450 455 460

Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val Ala Phe Asn Ser Leu
465 470 475 480

Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser Leu Ser Val Leu Ile
485 490 495

Ile Asp His Asn Ser Val Ser His Pro Ser Ala Asp Phe Phe Gln Ser
500 505 510

58182US002.ST25.txt

Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp Asn Pro Phe Gln Cys
515 520 525

Thr Cys Glu Leu Gly Glu Phe Val Lys Asn Ile Asp Gln Val Ser Ser
530 535 540

Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys Cys Asp Tyr Pro Glu
545 550 555 560

Ser Tyr Arg Gly Thr Leu Leu Lys Asp Phe His Met Ser Glu Leu Ser
565 570 575

Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Val Ala Thr Met Leu Val
580 585 590

Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr Leu Asp Leu Pro Trp
595 600 605

Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr Arg Arg Arg Ala Arg
610 615 620

Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe
625 630 635 640

Ile Ser Tyr Ser Gly His Asp Ser Phe Trp Val Lys Asn Glu Leu Leu
645 650 655

Pro Asn Leu Glu Lys Glu Gly Met Gln Ile Cys Leu His Glu Arg Asn
660 665 670

Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Thr Cys Ile Glu
675 680 685

Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro Asn Phe Val Gln Ser
690 695 700

Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His
705 710 715 720

Glu Gly Ser Asn Ser Leu Ile Leu Ile Leu Glu Pro Ile Pro Gln
725 730 735

Tyr Ser Ile Pro Ser Ser Tyr His Lys Leu Lys Ser Leu Met Ala Arg
740 745 750

Arg Thr Tyr Leu Glu Trp Pro Lys Glu Lys Ser Lys Arg Gly Leu Phe
755 760 765

58182US002.ST25.txt

Trp Ala Asn Leu Arg Ala Ala Ile Asn Ile Lys Leu Thr Glu Gln Ala
770 775 780

Lys Lys
785

<210> 3
<211> 2621
<212> DNA
<213> Homo sapiens

<400> 3
cagtgtttgg tggcaagg agatccaaa ggagacctat agtactccc aggagcttt 60
agtaccaag tgaaggtacc tgtgggctc attgtgccca ttgcttttc actgctttca 120
actggtagtt gtgggttgaa gcactggaca atgccacata ctttgtggat ggtgtgggtc 180
ttgggggtca tcattcgcct ctccaaggaa gaatcctcca atcaggcttc tctgtcttgt 240
gaccgcaatg gtatctgcaa gggcagctca ggatcttaa actccattcc ctcagggtc 300
acagaagctg taaaaagcct tgacctgtcc aacaacagga tcacccatcat tagcaacagt 360
gacctacaga ggtgtgtgaa cttccaggct ctggtgctga catccaatgg aattaacaca 420
atagaggaag attcttttc ttccctggc agtcttgaac atttagactt atcctataat 480
tacatatcta atttatcgtc ttccctggttc aagccccctt cttcttaac attcttaaac 540
ttactggaa atccttacaa aacccttaggg gaaacatctc tttttctca tctcacaaaa 600
ttgcaaattcc tgagagtggg aaatatggac acttcacta agattcaaag aaaagattt 660
gctggactta cttccattga ggaacttgag attgatgctt cagatctaca gagctatgag 720
ccaaaaagtt tgaagtcaat tcagaatgtt agtcatctga tccttcataat gaagcagcat 780
atttactgc tggagatttt tggatgtttt acaagttccg tggatgtttt ggaactgcga 840
gatactgatt tggacacttt ccattttca gaactatcca ctggtaaac aaattcattg 900
attaaaaagt ttacatttag aaatgtgaaa atcaccgatg aaagtttggatgtt tcaggatgt 960
aaactttga atcagatttc tggattgtt gaatttagatg ttgatgactg tacccttaat 1020
ggagttggta atttagagc atctgataat gacagagttt tagatccagg taaagtggaa 1080
acgttaacaa tccggaggct gcatattcca aggtttact tattttatgt tctgagcact 1140
ttatattcac ttacagaaaag agtaaaaaga atcacagtagt aaaaacagtaa agttttctg 1200
gttccttggtt tactttcaca acatttaaaa tcatttagatg acttggatct cagtaaaaat 1260
ttgatggttt aagaataactt gaaaaattca gcctgtgagg atgcctggcc ctctctacaa 1320
acttttaattt taaggcaaaa tcatttggca tcattggaaa aaaccggaga gactttgctc 1380
actctqaaaaa acttgactaa cattgatatc agtaagaata gttttcatttc tatgcctgaa 1440

58182US002.ST25.txt

acttgtcagt ggccagaaaa gatgaaatat ttgaacttat ccagcacacg aatacacagt	1500
gtaacaggct gcattcccaa gacactggaa atttagatg ttagcaacaa caatctcaat	1560
ttatttctt tgaatttgcc gcaactcaa gaacttata tttccagaaa taagttgatg	1620
actctaccag atgcctccct cttacccatg ttactagtat tgaaaatcag taggaatgca	1680
ataactacgt tttctaagga gcaacttgac tcatttcaca cactgaagac tttggaagct	1740
ggtggcaata acttcatttgc tcctgtgaa ttccttcct tcactcagga gcagcaagca	1800
ctggccaaag tcttgattga ttggccagca aattacctgt gtgactctcc atcccatgtg	1860
cgtggccagc aggttcagga tgtccgcctc tcgggtcg aatgtcacag gacagcactg	1920
gtgtctggca tgtgctgtgc tctgttcctg ctgatcctgc tcacgggggt cctgtgccac	1980
cgtttccatg gcctgtggta tatgaaaatg atgtgggcct ggctccaggc caaaaggaag	2040
cccaggaaag ctcccagcag gaacatctgc tatgatgcat ttgttctta cagtgagcgg	2100
gatgcctact gggtggagaa ctttatggtc caggagctgg agaacttcaa tcccccttc	2160
aagttgtgtc ttataagcg ggacttcatt cctggcaagt ggatcattga caatatcatt	2220
gactccattg aaaagagcca caaaactgtc tttgtgctt ctgaaaactt tgtgaagagt	2280
gagtggtgca agtatgaact ggacttctcc cattccgtc ttttgatga gaacaatgat	2340
gctgccattc tcattcttct ggagcccatt gagaaaaaaag ccattccccca gcgcttctgc	2400
aagctgcgga agataatgaa caccaagacc tacctggagt ggcccatgga cgaggctcag	2460
cggaaaggat tttggtaaa tctgagagct gcgataaagt cctaggttcc catatttaag	2520
accagtctt gtctagttgg gatcttatg tcactagtt tagttaaattt cattcagaca	2580
taattatata aaaactacgt ggatgtaccg tcatttgagg a	2621

<210> 4
<211> 784
<212> PRT
<213> Homo sapiens

<400> 4

Met Pro His Thr Leu Trp Met Val Trp Val Leu Gly Val Ile Ile Ser
1 5 10 15

Leu Ser Lys Glu Glu Ser Ser Asn Gln Ala Ser Leu Ser Cys Asp Arg
20 25 30

Asn Gly Ile Cys Lys Gly Ser Ser Gly Ser Leu Asn Ser Ile Pro Ser
35 40 45

Gly Leu Thr Glu Ala Val Lys Ser Leu Asp Leu Ser Asn Asn Arg Ile
50 55 60

58182US002.ST25.txt

Thr Tyr Ile Ser Asn Ser Asp Leu Gln Arg Cys Val Asn Leu Gln Ala
65 70 75 80

Leu Val Leu Thr Ser Asn Gly Ile Asn Thr Ile Glu Glu Asp Ser Phe
85 90 95

Ser Ser Leu Gly Ser Leu Glu His Leu Asp Leu Ser Tyr Asn Tyr Leu
100 105 110

Ser Asn Leu Ser Ser Ser Trp Phe Lys Pro Leu Ser Ser Leu Thr Phe
115 120 125

Leu Asn Leu Leu Gly Asn Pro Tyr Lys Thr Leu Gly Glu Thr Ser Leu
130 135 140

Phe Ser His Leu Thr Lys Leu Gln Ile Leu Arg Val Gly Asn Met Asp
145 150 155 160

Thr Phe Thr Lys Ile Gln Arg Lys Asp Phe Ala Gly Leu Thr Phe Leu
165 170 175

Glu Glu Leu Glu Ile Asp Ala Ser Asp Leu Gln Ser Tyr Glu Pro Lys
180 185 190

Ser Leu Lys Ser Ile Gln Asn Val Ser His Leu Ile Leu His Met Lys
195 200 205

Gln His Ile Leu Leu Leu Glu Ile Phe Val Asp Val Thr Ser Ser Val
210 215 220

Glu Cys Leu Glu Leu Arg Asp Thr Asp Leu Asp Thr Phe His Phe Ser
225 230 235 240

Glu Leu Ser Thr Gly Glu Thr Asn Ser Leu Ile Lys Lys Phe Thr Phe
245 250 255

Arg Asn Val Lys Ile Thr Asp Glu Ser Leu Phe Gln Val Met Lys Leu
260 265 270

Leu Asn Gln Ile Ser Gly Leu Leu Glu Leu Glu Phe Asp Asp Cys Thr
275 280 285

Leu Asn Gly Val Gly Asn Phe Arg Ala Ser Asp Asn Asp Arg Val Ile
290 295 300

Asp Pro Gly Lys Val Glu Thr Leu Thr Ile Arg Arg Leu His Ile Pro
305 310 315 320

58182US002.ST25.txt

Arg Phe Tyr Leu Phe Tyr Asp Leu Ser Thr Leu Tyr Ser Leu Thr Glu
325 330 335

Arg Val Lys Arg Ile Thr Val Glu Asn Ser Lys Val Phe Leu Val Pro
340 345 350

Cys Leu Leu Ser Gln His Leu Lys Ser Leu Glu Tyr Leu Asp Leu Ser
355 360 365

Glu Asn Leu Met Val Glu Glu Tyr Leu Lys Asn Ser Ala Cys Glu Asp
370 375 380

Ala Trp Pro Ser Leu Gln Thr Leu Ile Leu Arg Gln Asn His Leu Ala
385 390 395 400

Ser Leu Glu Lys Thr Gly Glu Thr Leu Leu Thr Leu Lys Asn Leu Thr
405 410 415

Asn Ile Asp Ile Ser Lys Asn Ser Phe His Ser Met Pro Glu Thr Cys
420 425 430

Gln Trp Pro Glu Lys Met Lys Tyr Leu Asn Leu Ser Ser Thr Arg Ile
435 440 445

His Ser Val Thr Gly Cys Ile Pro Lys Thr Leu Glu Ile Leu Asp Val
450 455 460

Ser Asn Asn Asn Leu Asn Leu Phe Ser Leu Asn Leu Pro Gln Leu Lys
465 470 475 480

Glu Leu Tyr Ile Ser Arg Asn Lys Leu Met Thr Leu Pro Asp Ala Ser
485 490 495

Leu Leu Pro Met Leu Leu Val Leu Lys Ile Ser Arg Asn Ala Ile Thr
500 505 510

Thr Phe Ser Lys Glu Gln Leu Asp Ser Phe His Thr Leu Lys Thr Leu
515 520 525

Glu Ala Gly Gly Asn Asn Phe Ile Cys Ser Cys Glu Phe Leu Ser Phe
530 535 540

Thr Gln Glu Gln Gln Ala Leu Ala Lys Val Leu Ile Asp Trp Pro Ala
545 550 555 560

Asn Tyr Leu Cys Asp Ser Pro Ser His Val Arg Gly Gln Gln Val Gln

565 58182US002.ST25.txt
570 575

Asp Val Arg Leu Ser Val Ser Glu Cys His Arg Thr Ala Leu Val Ser
580 585 590

Gly Met Cys Cys Ala Leu Phe Leu Leu Ile Leu Leu Thr Gly Val Leu
595 600 605

Cys His Arg Phe His Gly Leu Trp Tyr Met Lys Met Met Trp Ala Trp
610 615 620

Leu Gln Ala Lys Arg Lys Pro Arg Lys Ala Pro Ser Arg Asn Ile Cys
625 630 635 640

Tyr Asp Ala Phe Val Ser Tyr Ser Glu Arg Asp Ala Tyr Trp Val Glu
645 650 655

Asn Leu Met Val Gln Glu Leu Glu Asn Phe Asn Pro Pro Phe Lys Leu
660 665 670

Cys Leu His Lys Arg Asp Phe Ile Pro Gly Lys Trp Ile Ile Asp Asn
675 680 685

Ile Ile Asp Ser Ile Glu Lys Ser His Lys Thr Val Phe Val Leu Ser
690 695 700

Glu Asn Phe Val Lys Ser Glu Trp Cys Lys Tyr Glu Leu Asp Phe Ser
705 710 715 720

His Phe Arg Leu Phe Asp Glu Asn Asn Asp Ala Ala Ile Leu Ile Leu
725 730 735

Leu Glu Pro Ile Glu Lys Lys Ala Ile Pro Gln Arg Phe Cys Lys Leu
740 745 750

Arg Lys Ile Met Asn Thr Lys Thr Tyr Leu Glu Trp Pro Met Asp Glu
755 760 765

Ala Gln Arg Glu Gly Phe Trp Val Asn Leu Arg Ala Ala Ile Lys Ser
770 775 780

<210> 5
<211> 3057
<212> DNA
<213> Homo sapiens

<400> 5
cactttcgag agtgccgtct atttgccaca cacttccctg atgaaatgtc tggatttgga 60

58182US002.ST25.txt

ctaaagaaaa aaggaaaggc tagcagtcat ccaacagaat catgagacag actttgcctt	120
gtatctactt ttgggggggc ctttgccct ttggatgct gtgtcatcc tccaccacca	180
agtgcactgt tagccatgaa gttgctgact gcagccacct gaagttgact caggtacccg	240
atgatctacc cacaacata acagtgttga accttaccca taatcaactc agaagattac	300
cagccgccaa cttcacaagg tatagccagc taactagctt ggatgttagga tttaacacca	360
tctcaaaact ggagccagaa ttgtgccaga aacttccat gttaaaagtt ttgaacctcc	420
agcacaatga gctatctcaa ctttctgata aaacctttgc cttctgcacg aatttactg	480
aactccatct catgtccaac tcaatccaga aaattaaaaa taatccctt gtcaagcaga	540
agaatttaat cacattagat ctgtctata atggcttgc atctacaaaa ttaggaactc	600
agttcagct ggaaaatctc caagagcttc tattatcaa caataaaatt caagcgctaa	660
aaagtgaaga actggatatc tttgccaatt catcttaaa aaaatttagag ttgtcatcga	720
atcaaattaa agagtttct ccagggtgtt ttcacgcaat tggaagatta tttggctct	780
ttctgaacaa tgtccagctg ggtcccagcc ttacagagaa gctatgttg gaattagcaa	840
acacaagcat tcggaatctg tctctgagta acagccagct gtccaccacc agcaatacaa	900
ctttcttggg actaaagtgg acaaatctca ctatgctcga tcttcctac aacaacttaa	960
atgtggttgg taacgattcc tttgcttggc ttccacaact agaatatttc ttcctagagt	1020
ataataatat acagcatttg ttttctact ctttgcacgg gctttcaat gtgaggtacc	1080
tgaatttcaa acggctttt actaaacaaa gtatcccct tgcctcactc cccaaaggatt	1140
atgatttttc ttttcagtgg ctaaaatgtt tggagcacct taacatggaa gataatgata	1200
ttccaggcat aaaaagcaat atgttcacag gattgataaa cctgaaatac ttaagtctat	1260
ccaaactcctt tacaagtttg cgaactttga caaatgaaac atttgtatca cttgctcatt	1320
ctcccttaca catactcaac ctaaccaaga ataaaatctc aaaaatagag agtgatgctt	1380
tctcttgggt gggccaccta gaagtacttg acctggcct taatgaaatt gggcaagaac	1440
tcacaggcca ggaatggaga ggtctagaaa atatttcga aatctatctt tcctacaaca	1500
agtacctgca gctgactagg aactcctttg cttggtccc aagcctcaa cgactgatgc	1560
tccgaagggt ggcccttaaa aatgtggata gctctccttc accattccag cctttcgta	1620
acttgaccat tctggatcta agcaacaaca acatagccaa cataaatgat gacatgttg	1680
agggtcttga gaaactagaa attctcgatt tgcagcataa caacttagca cggctctgga	1740
aacacgcaaa ccctgggtgtt cccatttatt tcctaaaggg tctgtctcac ctccacatcc	1800
ttaacttggg gtccaacggc tttgacgaga tcccagttga ggtcttcaag gatttatttg	1860
aactaaagat catcgatttta ggattgaata atttaaacac acttccagca tctgtcttta	1920
ataatcaggt gtctctaaag tcattgaacc ttcagaagaa tctcataaca tccgttgaga	1980

58182US002.ST25.txt

agaaggttt	cggccagct	ttcaggaacc	tgactgagtt	agatatgcgc	tttaatccct	2040
ttgattgcac	gtgtgaaagt	attgcctgg	ttgttaattg	gattaacgag	acccatacca	2100
acatccctga	gctgtcaagc	ca taccttt	gcaacactcc	acctcactat	catgggttcc	2160
cagtgagact	tttgataca	tcatcttgca	aagacagtgc	ccccttgaa	ctcttttca	2220
tgatcaatac	cagtatcctg	ttgattttt	tcttattgt	acttctcatc	cactttgagg	2280
gctggaggat	atcttttat	tggaatgtt	cagtacatcg	agttcttggt	ttcaaagaaa	2340
tagacagaca	gacagaacag	tttgaatatg	cagcatatat	aattcatgcc	tataaagata	2400
aggattgggt	ctgggaacat	ttctcttcaa	tggaaaagga	agaccaatct	ctcaaatttt	2460
gtctggaga	aaggacttt	gaggcgggtg	ttttgaact	agaagcaatt	gttaacagca	2520
tcaaaagaag	cagaaaaatt	attttgtt	taacacacca	tctattaaaa	gaccattat	2580
gcaaaagatt	caaggtacat	catgcagttc	aacaagctat	tgaacaaaat	ctggattcca	2640
ttatatttgt	tttccttgag	gagattccag	attataaact	gaaccatgca	ctctgttgc	2700
gaagaggaat	gtttaatct	caactgcac	tgaactggcc	agttcagaaa	gaacggatag	2760
gtgccttcg	tcataaattt	caagtagcac	ttggatccaa	aaactctgt	cattaaattt	2820
atttaaat	tcaattagca	aaggagaaac	tttctcaatt	taaaaagttc	tatggcaa	2880
ttaagtttc	cataaagg	ttataattt	tttattcata	tttgtaatg	attatattct	2940
atcacaatta	catctcttct	aggaaaatgt	gtctccttat	ttcaggccta	ttttgacaa	3000
ttgacttaat	tttacccaaa	ataaaacata	taagcacgta	aaaaaaaaaa	aaaaaaaaaa	3057

<210> 6

<211> 904

<212> PRT

<213> Homo sapiens

<400> 6

Met	Arg	Gln	Thr	Leu	Pro	Cys	Ile	Tyr	Phe	Trp	Gly	Gly	Leu	Leu	Pro
1				5					10				15		

Phe	Gly	Met	Leu	Cys	Ala	Ser	Ser	Thr	Thr	Lys	Cys	Thr	Val	Ser	His
		20						25				30			

Glu	Val	Ala	Asp	Cys	Ser	His	Leu	Lys	Leu	Thr	Gln	Val	Pro	Asp	Asp
	35						40				45				

Leu	Pro	Thr	Asn	Ile	Thr	Val	Leu	Asn	Leu	Thr	His	Asn	Gln	Leu	Arg
	50				55				60						

Arg	Leu	Pro	Ala	Ala	Asn	Phe	Thr	Arg	Tyr	Ser	Gln	Leu	Thr	Ser	Leu
65					70			75			80				

58182US002.ST25.txt

Asp Val Gly Phe Asn Thr Ile Ser Lys Leu Glu Pro Glu Leu Cys Gln
85 90 95

Lys Leu Pro Met Leu Lys Val Leu Asn Leu Gln His Asn Glu Leu Ser
100 105 110

Gln Leu Ser Asp Lys Thr Phe Ala Phe Cys Thr Asn Leu Thr Glu Leu
115 120 125

His Leu Met Ser Asn Ser Ile Gln Lys Ile Lys Asn Asn Pro Phe Val
130 135 140

Lys Gln Lys Asn Leu Ile Thr Leu Asp Leu Ser His Asn Gly Leu Ser
145 150 155 160

Ser Thr Lys Leu Gly Thr Gln Val Gln Leu Glu Asn Leu Gln Glu Leu
165 170 175

Leu Leu Ser Asn Asn Lys Ile Gln Ala Leu Lys Ser Glu Glu Leu Asp
180 185 190

Ile Phe Ala Asn Ser Ser Leu Lys Lys Leu Glu Leu Ser Ser Asn Gln
195 200 205

Ile Lys Glu Phe Ser Pro Gly Cys Phe His Ala Ile Gly Arg Leu Phe
210 215 220

Gly Leu Phe Leu Asn Asn Val Gln Leu Gly Pro Ser Leu Thr Glu Lys
225 230 235 240

Leu Cys Leu Glu Leu Ala Asn Thr Ser Ile Arg Asn Leu Ser Leu Ser
245 250 255

Asn Ser Gln Leu Ser Thr Thr Ser Asn Thr Thr Phe Leu Gly Leu Lys
260 265 270

Trp Thr Asn Leu Thr Met Leu Asp Leu Ser Tyr Asn Asn Leu Asn Val
275 280 285

Val Gly Asn Asp Ser Phe Ala Trp Leu Pro Gln Leu Glu Tyr Phe Phe
290 295 300

Leu Glu Tyr Asn Asn Ile Gln His Leu Phe Ser His Ser Leu His Gly
305 310 315 320

Leu Phe Asn Val Arg Tyr Leu Asn Leu Lys Arg Ser Phe Thr Lys Gln
Page 13

58182US002.ST25.txt

325 330 335

Ser Ile Ser Leu Ala Ser Leu Pro Lys Ile Asp Asp Phe Ser Phe Gln
340 345 350

Trp Leu Lys Cys Leu Glu His Leu Asn Met Glu Asp Asn Asp Ile Pro
355 360 365

Gly Ile Lys Ser Asn Met Phe Thr Gly Leu Ile Asn Leu Lys Tyr Leu
370 375 380

Ser Leu Ser Asn Ser Phe Thr Ser Leu Arg Thr Leu Thr Asn Glu Thr
385 390 395 400

Phe Val Ser Leu Ala His Ser Pro Leu His Ile Leu Asn Leu Thr Lys
405 410 415

Asn Lys Ile Ser Lys Ile Glu Ser Asp Ala Phe Ser Trp Leu Gly His
420 425 430

Leu Glu Val Leu Asp Leu Gly Leu Asn Glu Ile Gly Gln Glu Leu Thr
435 440 445

Gly Gln Glu Trp Arg Gly Leu Glu Asn Ile Phe Glu Ile Tyr Leu Ser
450 455 460

Tyr Asn Lys Tyr Leu Gln Leu Thr Arg Asn Ser Phe Ala Leu Val Pro
465 470 475 480

Ser Leu Gln Arg Leu Met Leu Arg Arg Val Ala Leu Lys Asn Val Asp
485 490 495

Ser Ser Pro Ser Pro Phe Gln Pro Leu Arg Asn Leu Thr Ile Leu Asp
500 505 510

Leu Ser Asn Asn Asn Ile Ala Asn Ile Asn Asp Asp Met Leu Glu Gly
515 520 525

Leu Glu Lys Leu Glu Ile Leu Asp Leu Gln His Asn Asn Leu Ala Arg
530 535 540

Leu Trp Lys His Ala Asn Pro Gly Gly Pro Ile Tyr Phe Leu Lys Gly
545 550 555 560

Leu Ser His Leu His Ile Leu Asn Leu Glu Ser Asn Gly Phe Asp Glu
565 570 575

58182US002.ST25.txt

Ile Pro Val Glu Val Phe Lys Asp Leu Phe Glu Leu Lys Ile Ile Asp
580 585 590

Leu Gly Leu Asn Asn Leu Asn Thr Leu Pro Ala Ser Val Phe Asn Asn
595 600 605

Gln Val Ser Leu Lys Ser Leu Asn Leu Gln Lys Asn Leu Ile Thr Ser
610 615 620

Val Glu Lys Lys Val Phe Gly Pro Ala Phe Arg Asn Leu Thr Glu Leu
625 630 635 640

Asp Met Arg Phe Asn Pro Phe Asp Cys Thr Cys Glu Ser Ile Ala Trp
645 650 655

Phe Val Asn Trp Ile Asn Glu Thr His Thr Asn Ile Pro Glu Leu Ser
660 665 670

Ser His Tyr Leu Cys Asn Thr Pro Pro His Tyr His Gly Phe Pro Val
675 680 685

Arg Leu Phe Asp Thr Ser Ser Cys Lys Asp Ser Ala Pro Phe Glu Leu
690 695 700

Phe Phe Met Ile Asn Thr Ser Ile Leu Leu Ile Phe Ile Phe Ile Val
705 710 715 720

Leu Leu Ile His Phe Glu Gly Trp Arg Ile Ser Phe Tyr Trp Asn Val
725 730 735

Ser Val His Arg Val Leu Gly Phe Lys Glu Ile Asp Arg Gln Thr Glu
740 745 750

Gln Phe Glu Tyr Ala Ala Tyr Ile Ile His Ala Tyr Lys Asp Lys Asp
755 760 765

Trp Val Trp Glu His Phe Ser Ser Met Glu Lys Glu Asp Gln Ser Leu
770 775 780

Lys Phe Cys Leu Glu Glu Arg Asp Phe Glu Ala Gly Val Phe Glu Leu
785 790 795 800

Glu Ala Ile Val Asn Ser Ile Lys Arg Ser Arg Lys Ile Ile Phe Val
805 810 815

Ile Thr His His Leu Leu Lys Asp Pro Leu Cys Lys Arg Phe Lys Val
820 825 830

58182US002.ST25.txt

His His Ala Val Gln Gln Ala Ile Glu Gln Asn Leu Asp Ser Ile Ile
 835 840 845

Leu Val Phe Leu Glu Glu Ile Pro Asp Tyr Lys Leu Asn His Ala Leu
 850 855 860

Cys Leu Arg Arg Gly Met Phe Lys Ser His Cys Ile Leu Asn Trp Pro
 865 870 875 880

Val Gln Lys Glu Arg Ile Gly Ala Phe Arg His Lys Leu Gln Val Ala
 885 890 895

Leu Gly Ser Lys Asn Ser Val His
 900

<210> 7
<211> 3811
<212> DNA
<213> Homo sapiens

<400> 7	
acaggggccac tgctgctcac agaagcagtg aggatgtgc caggatgtg tctgcctcg	60
gcctggctgg gactctgatc ccagccatgg ctttcctctc ctgcgtgaga ccagaaagct	120
gggagccctg cgtggagact tggccctaaa ccacacagaa gagctggcat gaaaccaga	180
gcttcagac tccggagcct cagcccttca ccccgattcc attgcttctt gctaaatgct	240
gccgttttat cacggaggtg gttcctaata ttacttatca atgcatggag ctgaatttct	300
acaataatccc cgacaacctc cccttctcaa ccaagaacct ggacctgagc tttaatcccc	360
tgaggcattt aggcagctat agtttcttca gtttcccaga actgcaggtg ctggatttat	420
ccaggtgtga aatccagaca attgaagatg gggcatatca gagcctaagc cacctctcta	480
ccttaatatt gacaggaaac cccatccaga gtttagccct gggagccttt tctggactat	540
caagtttaca gaagctggtg gctgtggaga caaatctagc atctctagag aacttcccc	600
ttggacatct caaaactttt aaaaaactta atgtggctca caatcttatac caatcttca	660
aattacctga gtatttttct aatctgacca atcttagagca cttggacctt tccagcaaca	720
agattcaaag tatttattgc acagacttgc gggttctaca tcaaattgccc ctactcaatc	780
tctctttaga cctgtccctg aaccctatga actttatcca accaggtgca tttaaagaaa	840
ttaggcttca taagctgact ttaagaaata atttttagatg tttaaatgta atgaaaactt	900
gtattcaagg tctggctgg ttagaagtcc atcgtttgt tctggagaa tttagaaatg	960
aaggaaactt ggaaaagtt gacaaatctg ctctagaggg cctgtgcaat ttgaccattg	1020
aagaattccg attagcatac ttagactact acctcgatga tattattgac ttatctaatt	1080

58182us002.ST25.txt

gtttgacaaa	tgttcttca	tttccctgg	tgagtgtac	tattgaaagg	gtaaaagact	1140
tttcttataa	tttcggatgg	caacattag	aattagttaa	ctgtaaattt	ggacagttc	1200
ccacattgaa	actcaaatct	ctcaaaaggc	ttactttcac	ttccaacaaa	ggtggaaatg	1260
cttttcaga	agttgatcta	ccaaggcttg	agtttctaga	tctcagtaga	aatggcttga	1320
gtttcaaagg	ttgctgttct	caaagtgatt	ttgggacaac	cagcctaaag	tatttagatc	1380
ttagctcaa	tggtgttatt	accatgagtt	caaacttctt	gggcttagaa	caactagaac	1440
atctggattt	ccagcattcc	aatttgaac	aatgagtga	gtttcagta	ttccttatcac	1500
tcagaaacct	catttacctt	gacatttctc	atactcacac	cagagttgct	ttcaatggca	1560
tcttcaatgg	cttgcgttct	ctcgaagtct	tgaaaatggc	tggcaattct	ttccaggaaa	1620
acttccttcc	agatatcttc	acagagctga	gaaacttgac	cttcctggac	ctctctcagt	1680
gtcaactgga	gcagttgtct	ccaacagcat	ttaactcact	ctccagtctt	caggtactaa	1740
atatgagcca	caacaacttc	tttcattgg	atacgttcc	ttataagtgt	ctgaactccc	1800
tccaggttct	tgattacagt	ctcaatcaca	taatgacttc	caaaaaacag	gaactacagc	1860
attttccaag	tagtcttagct	ttcttaaattc	ttactcagaa	tgactttgct	tgtacttgg	1920
aacaccagag	tttcctgcaa	tggatcaagg	accagaggca	gctcttggtg	gaagttgaac	1980
gaatggaatg	tgcaacacct	tcagataagc	agggcatgcc	tgtgctgagt	ttgaatatca	2040
cctgtcagat	gaataagacc	atcattggtg	tgtcggtcct	cagtgtgctt	gtatgtatcg	2100
ttgttagcagt	tctggtctat	aagttctatt	ttcacctgat	gcttcttgct	ggctgcataa	2160
agtatggtag	aggtgaaaac	atctatgatg	cctttgttat	ctactcaagc	caggatgagg	2220
actgggtaag	gaatgagcta	gtaaagaatt	tagaagaagg	ggtgcctcca	tttcagctct	2280
gccttcacta	cagagacttt	attcccggtg	tggccattgc	tgccaacatc	atccatgaag	2340
gtttccataa	aagccgaaag	gtgattgttg	tgggtccca	gcacttcatc	cagagccgct	2400
ggtgtatctt	tgaatatgag	attgctcaga	cctggcagtt	tctgagcagt	cgtgctggta	2460
tcatcttcat	tgtcctgcag	aagggtggaga	agaccctgct	caggcagcag	gtggagctgt	2520
accgccttct	cagcaggaac	acttacctgg	agtgggagga	cagtgtcctg	gggcggcaca	2580
tcttctggag	acgactcaga	aaagccctgc	tggatggtaa	atcatggaat	ccagaaggaa	2640
cagtgggtac	aggatgcaat	tggcaggaag	caacatctat	ctgaagagga	aaaataaaaa	2700
cctcctgagg	catttcttgc	ccagctgggt	ccaacacttg	ttcagttaat	aagtattaaa	2760
tgctgccaca	tgtcaggcct	tatgctaagg	gtgagtaatt	ccatggtgca	ctagatatgc	2820
agggctgcta	atctcaagga	gcttccagtg	cagaggaaat	aaatgctaga	ctaaaataca	2880
gagtcttcca	ggtgggcatt	tcaaccaact	cagtcaagga	acccatgaca	aagaaagtca	2940
tttcaactct	tacctcatca	agttgaataa	agacagagaa	aacagaaaga	gacattgttc	3000

58182US002.ST25.txt

ttttcctgag	tctttgaat	ggaaattgta	ttatgttata	gccatcataa	aaccatttg	3060
gtagtttga	ctgaactggg	tgttcacttt	ttccttttg	attgaataca	atttaaattc	3120
tacttgatga	ctgcagtcgt	caaggggctc	ctgatgcaag	atgccccttc	catttaagt	3180
ctgtctccctt	acagaggtta	aagtctaatg	gctaattcct	aaggaaacct	gattaacaca	3240
tgctcacaac	catcctggtc	attctcgAAC	atgttctatt	ttttaactaa	tcacccctga	3300
tatattttta	tttttatata	tccagtttc	attttttac	gtctgccta	taagctaata	3360
tcataaataa	ggttgtttaa	gacgtgcttc	aaatatccat	attaaccact	attttcaag	3420
gaagtatgga	aaagtacact	ctgtcacttt	gtcactcgat	gtcattccaa	agttattgcc	3480
tactaagtaa	tgactgtcat	gaaagcagca	ttgaaataat	ttgtttaaag	ggggcactct	3540
tttaaacggg	aagaaaattt	ccgcttcctg	gtcttatcat	ggacaatttg	ggctataggc	3600
atgaaggaag	tgggattacc	tcaggaagtc	acctttctt	gattccagaa	acatatggc	3660
tgataaaaccc	gggtgacct	catgaaatga	gttgagcag	atgtttattt	tttcagaac	3720
aagtgatgtt	tgatggacct	atgaatctat	ttagggagac	acagatggct	gggatccctc	3780
ccctgtaccc	ttctcactga	caggagaact	a			3811

<210> 8

<211> 799

<212> PRT

<213> Homo sapiens

<400> 8

Met	Glu	Leu	Asn	Phe	Tyr	Lys	Ile	Pro	Asp	Asn	Leu	Pro	Phe	Ser	Thr
1						5				10				15	

Lys	Asn	Leu	Asp	Leu	Ser	Phe	Asn	Pro	Leu	Arg	His	Leu	Gly	Ser	Tyr
						20			25				30		

Ser	Phe	Phe	Ser	Phe	Pro	Glu	Leu	Gln	Val	Leu	Asp	Leu	Ser	Arg	Cys
						35		40					45		

Glu	Ile	Gln	Thr	Ile	Glu	Asp	Gly	Ala	Tyr	Gln	Ser	Leu	Ser	His	Leu
						50		55				60			

Ser	Thr	Leu	Ile	Leu	Thr	Gly	Asn	Pro	Ile	Gln	Ser	Leu	Ala	Leu	Gly
						65			70			75			80

Ala	Phe	Ser	Gly	Leu	Ser	Ser	Leu	Gln	Lys	Leu	Val	Ala	Val	Glu	Thr
								85		90				95	

Asn	Leu	Ala	Ser	Leu	Glu	Asn	Phe	Pro	Ile	Gly	His	Leu	Lys	Thr	Leu
								100		105			110		

58182US002.ST25.txt

Lys Glu Leu Asn Val Ala His Asn Leu Ile Gln Ser Phe Lys Leu Pro
115 120 125

Glu Tyr Phe Ser Asn Leu Thr Asn Leu Glu His Leu Asp Leu Ser Ser
130 135 140

Asn Lys Ile Gln Ser Ile Tyr Cys Thr Asp Leu Arg Val Leu His Gln
145 150 155 160

Met Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn
165 170 175

Phe Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr
180 185 190

Leu Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln
195 200 205

Gly Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg
210 215 220

Asn Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu
225 230 235 240

Cys Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr
245 250 255

Leu Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser
260 265 270

Phe Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr
275 280 285

Asn Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln
290 295 300

Phe Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser
305 310 315 320

Asn Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu
325 330 335

Phe Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser
340 345 350

Gln Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe
Page 19

58182US002.ST25.txt
355 360 365

Asn Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu
370 375 380

Glu His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met Ser Glu Phe
385 390 395 400

Ser Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His
405 410 415

Thr His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser
420 425 430

Leu Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu
435 440 445

Pro Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser
450 455 460

Gln Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser
465 470 475 480

Ser Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp
485 490 495

Thr Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser
500 505 510

Leu Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro
515 520 525

Ser Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr
530 535 540

Cys Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu
545 550 555 560

Leu Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln
565 570 575

Gly Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr
580 585 590

Ile Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala
595 600 605

58182US002.ST25.txt

Val Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys
 610 615 620

Ile Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr
 625 630 635 640

Ser Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu
 645 650 655

Glu Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe
 660 665 670

Ile Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His
 675 680 685

Lys Ser Arg Lys Val Ile Val Val Val Ser Gln His Phe Ile Gln Ser
 690 695 700

Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu
 705 710 715 720

Ser Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys
 725 730 735

Thr Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn
 740 745 750

Thr Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp
 755 760 765

Arg Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu
 770 775 780

Gly Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile
 785 790 795

<210> 9
<211> 1261
<212> DNA
<213> Homo sapiens

<400> 9
tggatataa ctcataacaa gttcatttgt gaatgtgaac ttagcacttt tatcaattgg 60
cttaattccc ttccaccagg agtatttagc catctgactg cattaagggg actaagcctc 120
aactccaaca ggctgacagt tctttctcac aatgattac ctgctaattt agagatcctg 180
gacatatcca ggaaccagct cctagctcct aatcctgatg tatttgatc acttagtg 240
ttggatataa ctcataacaa gttcatttgt gaatgtgaac ttagcacttt tatcaattgg 300

58182US002.ST25.txt

cttaatcaca ccaatgtcac tatacgctgg ctcctgcag acatatattg tgtgtaccct 360
gactcgttct ctggggtttc cctcttctct ctttccacgg aagggttgtga tgaagaggaa 420
gtcttaaagt ccctaaagtt ctcccctttc attgtatgca ctgtcactct gactctgttc 480
ctcatgacca tcctcacagt cacaaagttc cggggcttct gtttatctg ttataagaca 540
gcccagagac tgggtttcaa ggaccatccc cagggcacag aacctgatat gtacaaatat 600
gatgcctatt tgtgcttcag cagcaaagac ttcacatggg tgcagaatgc tttgctcaaa 660
cacctggaca ctcaatacag tgacccaaaac agattcaacc tgtgctttga agaaagagac 720
tttgtcccg gagaaaaccg cattgccaat atccaggatg ccatctggaa cagtagaaag 780
atcgttgtc ttgtgagcag acacttcctt agagatggct ggtgccttga agccttcagt 840
tatgcccagg gcaggtgctt atctgacctt aacagtgctc tcatcatggt ggtgggtggg 900
tccttgccttcc agtaccagtt gatgaaacat caatccatca gaggctttgt acagaaacag 960
cagtatttga ggtggcctga ggtatctccag gatgttggt ggtttcttca taaactctct 1020
caacagatac taaagaaaga aaaagaaaaag aagaaagaca ataacattcc gttgcaaact 1080
gtagcaacca tctcctaattc aaaggagcaa tttccaacctt atctcaagcc acaaataact 1140
cttcactttg tatttgcacc aagttatcat tttggggtcc tctctggagg tttttttttt 1200
cttttgcta ctatgaaaac aacataaaatc tctcaattt cgtatcaaaa aaaaaaaaaaa 1260
a 1261

<210> 10
<211> 204
<212> PRT
<213> Homo sapiens

<400> 10

Met Thr Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile Cys
1 5 . 10 15

Tyr Lys Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly Thr
20 25 30

Glu Pro Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser Lys
35 40 45

Asp Phe Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr Gln
50 55 60

Tyr Ser Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp Phe
65 70 75 80

58182us002.ST25.txt

Val Pro Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp Asn
85 90 95

Ser Arg Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp Gly
100 105 110

Trp Cys Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser Asp
115 120 125

Leu Asn Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln Tyr
130 135 140

Gln Leu Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln Gln
145 150 155 160

Tyr Leu Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu His
165 170 175

Lys Leu Ser Gln Gln Ile Leu Lys Lys Glu Lys Lys Lys Lys Asp
180 185 190

Asn Asn Ile Pro Leu Gln Thr Val Ala Thr Ile Ser
195 200

<210> 11
<211> 2753
<212> DNA
<213> Homo sapiens

<400> 11	
agaattttgga ctcatatcaa gatgctctga agaagaacaa cccttagga tagccactgc	60
aacatcatga ccaaagacaa agaacctatt gttaaaagct tccattttgt ttgccttatg	120
atcataatag ttggaaccag aatccagttc tccgacggaa atgaatttgc agtagacaag	180
tcaaaaagag gtcttattca tgttccaaaa gacctaccgc tgaaaaccaa agtcttagat	240
atgtctcaga actacatcgc tgagcttcag gtctctgaca tgagcttct atcagagttg	300
acagtttga gactttccca taacagaatc cagctacttg atttaagtgt tttcaagttc	360
aaccaggatt tagaatattt ggatttatct cataatcgt tgcaaaagat atcctgccat	420
cctattgtga gtttcaggca tttagatctc tcattcaatg atttcaaggc cctgccatc	480
tgttaggaat ttggcaactt atcacaactg aatttcttgg gattgagtgc tatgaagctg	540
caaaaattag atttgctgcc aattgctcac ttgcatctaa gttatatcct tctggattta	600
agaaaattatt atataaaaga aaatgagaca gaaagtctac aaattctgaa tgcaaaaacc	660
cttcaccttg ttttcaccc aactagttt atcgctatcc aagtgaacat atcagttat	720
acttttagggt gcttacaact gactaatatt aaattgaatg atgacaactg tcaagtttc	780

58182us002.ST25.txt

ataaaatttt tatcagaact caccagaggt tcaaccc tac tgaatttac cctcaaccac	840
atagaaacga ctggaaatg cctggcaga gtcttcaat ttcttgcc caaacctgtg	900
gaatatctca atatttacaa tttaacaata attgaaagca ttctgtgaaga agatttact	960
tattctaaaa cgacattgaa agcattgaca atagaacata tcacgaacca agttttctg	1020
tttcacaga cagcttgta caccgttt tctgagatga acattatgtat gttaaccatt	1080
tcagatacac ctttataca catgctgtgt cctcatgcac caagcacatt caagttttg	1140
aactttaccc agaacgttt cacagatgt attttgaaa aatgttccac gttagttaaa	1200
ttggagacac ttatcttaca aaaaaatgga ttaaaagacc tttcaaagt aggtctcatg	1260
acgaaggata tgcccttctt ggaaatactg gatgttagct ggaattctt ggaatctggt	1320
agacataaag aaaactgcac ttgggtttag agtatagtgg tgttaaattt gtcttcaaatt	1380
atgcttactg actctgtttt cagatgtta cctcccagga tcaaggtact tgatcttac	1440
agcaataaaaa taaagagcgt tcctaaacaa gtcgtaaaac tggaaagctt gcaagaactc	1500
aatgttgctt tcaattctt aactgaccctt cctggatgtg gcagctttag cagccttct	1560
gtattgatca ttgatcaca tttagttcc caccatcg ctgatttctt ccagagctgc	1620
cagaagatga ggtcaataaa agcaggggac aatccattcc aatgtacctg tgagctaaga	1680
gaatttgtca aaaatataga ccaagtatca agtgaagtgt tagagggctg gcctgattct	1740
tataagtgtg actacccaga aagttataga ggaagcccac taaaggactt tcacatgtct	1800
gaattatcct gcaacataac tctgctgatc gtcaccatcg gtgccaccat gctgggttt	1860
gctgtgactg tgacccctt ctgcattctac ttggatctgc cctggtatct caggatggtg	1920
tgccagtgga cccagactcg gcgcagggcc aggaacatac cttttagaaga actccaaaga	1980
aacctccagt ttcatgcttt tatttcatat agtgaacatg attctgcctg ggtgaaaagt	2040
gaattggtagt cttacctaga aaaagaagat atacagattt gtcttcatga gaggaacttt	2100
gtccctggca agagcattgt ggaaaatatc atcaactgca ttgagaagag ttacaagtcc	2160
atctttgttt tgtctccaa cttgtccag agttagtggt gccattacga actctatttt	2220
gcccatcaca atctcttca tgaaggatct aataactta tcctcatctt actggAACCC	2280
attccacaga acagcattcc caacaagtac cacaagctga aggctctcat gacgcagcgg	2340
acttatttgc agtggccaa ggagaaaagc aaacgtggc tctttggc taacattaga	2400
gccgctttta atatgaaatt aacactagtc actgaaaaca atgatgtgaa atctaaaaaa	2460
aatttaggaa attcaactta agaaaccatt atttacttgg atgatggta atagtagtgc	2520
cgttaagtaac tgtctggagg tgcctccatt atcctcatgc cttcaggaaa gacttaacaa	2580
aaacaatgtt tcatctgggg aactgagcta ggcggtgagg ttagcctgcc agtttagagac	2640

58182US002.ST25.txt

agcccaagtct cttctggttt aatcattatg tttcaaattg aaacagtctc ttttgagtaa 2700
atgctcagtt tttcagctcc tctccactct gctttcccaa atggattctg ttg 2753

<210> 12
<211> 796
<212> PRT
<213> Homo sapiens

<400> 12

Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys
1 5 10 15

Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn
20 25 30

Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys
35 40 45

Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile
50 55 60

Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val
65 70 75 80

Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe
85 90 95

Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu
100 105 110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu
115 120 125

Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn
130 135 140

Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys
145 150 155 160

Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu
165 170 175

Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln
180 185 190

Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu
195 200 205

58182US002.ST25.txt

Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln
210 215 220

Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys
225 230 235 240

Phe Leu Ser Glu Leu Thr Arg Gly Ser Thr Leu Leu Asn Phe Thr Leu
245 250 255

Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe
260 265 270

Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile
275 280 285

Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu
290 295 300

Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser
305 310 315 320

Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu
325 330 335

Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro
340 345 350

Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser
355 360 365

Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu
370 375 380

Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys
385 390 395 400

Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu
405 410 415

Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val
420 425 430

Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu
435 440 445

Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser
450 455 460

58182US002.ST25.txt

Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val
465 470 475 480

Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser
485 490 495

Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala
500 505 510

Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp
515 520 525

Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile
530 535 540

Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys
545 550 555 560

Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His
565 570 575

Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly
580 585 590

Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr
595 600 605

Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr
610 615 620

Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu
625 630 635 640

Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val
645 650 655

Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys
660 665 670

Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile
675 680 685

Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro
690 695 700

Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His
Page 27

58182US002.ST25.txt

705	710	715	720
His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu Leu			
	725	730	735
Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys			
	740	745	750
Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser			
	755	760	765
Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys			
	770	775	780
Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser			
	785	790	795

<210> 13
<211> 5007
<212> DNA
<213> Homo sapiens

<400> 13
actccagata taggatcact ccatgccatc aagaaagttg atgctattgg gcccacatctca 60
agctgatctt ggcacctctc atgctctgct ctcttcaacc agacctctac attccatttt 120
ggaagaagac taaaaatggt gttccaatg tggacactga agagacaaat tcttatcctt 180
tttaacataa tcctaatttc caaactcctt gggcttagat ggttcctaa aactctgccc 240
tgtgatgtca ctctggatgt tccaaagaac catgtgatcg tggactgcac agacaaggcat 300
ttgacagaaa ttccctggagg tattcccacg aacaccacga acctcaccct caccattaac 360
cacataccag acatctcccc agcgtcctt cacagactgg accatctggt agagatcgat 420
ttcagatgca actgtgtacc tattccactg gggtaaaaaa acaacatgtg catcaagagg 480
ctgcagatta aacccagaag cttagtgga ctcacttatt taaaatccct ttacctggat 540
gaaaaccagc tactagagat accgcaggc ctccgccta gcttacagct tctcagcctt 600
gaggccaaca acatctttc catcagaaaa gagaatctaa cagaactggc caacatagaa 660
atactctacc tggccaaaa ctgttattat cgaaatcctt gttatgtttc atattcaata 720
gagaaagatg cttccctaaa cttgacaaag taaaaagtgc tctccctgaa agataacaat 780
gtcacagccg tccctactgt tttgccatct actttaacag aactatatct ctacaacaac 840
atgattgcaa aaatccaaga agatgattt aataacctca accaattaca aattcttgac 900
ctaagtggaa attgccctcg ttgttataat gccccatttc cttgtgcgcc gtgtaaaaat 960
aattctcccc tacagatccc tgtaaatgct tttgatgcgc tgacagaatt aaaagttta 1020

58182US002.ST25.txt

cgtctacaca	gtaactctct	tcagcatgtg	ccccaagat	ggtttaagaa	catcaacaaa	1080
ctccaggaac	tggatctgtc	ccaaaacttc	ttggccaaag	aaattgggga	tgctaaattt	1140
ctgcatttc	tccccagcct	catccaattt	gatctgtctt	tcaattttga	acttcaggtc	1200
tatcggtcat	ctatgaatct	atcacaaggca	ttttcttcac	tgaaaaggct	gaaaattctg	1260
cggatcagag	gatatgtctt	taaagagttt	aaaagctta	acctctgcc	attacataat	1320
cttcaaaatc	ttgaagttct	tgatcttggc	actaacttta	taaaaattgc	taacctcagc	1380
atgtttaaac	aattttaaag	actgaaagtc	atagatctt	cagtgaataa	aatatcacct	1440
tcaggagatt	caagtgaagt	tggcttctgc	tcaaattgcca	gaacttctgt	agaaaagttat	1500
gaaccccagg	tccttggaca	attacattat	ttcagatatg	ataagtatgc	aaggagttgc	1560
agattcaaaa	acaaagaggc	ttcttcatg	tctgttaatg	aaagctgcta	caagtatggg	1620
cagaccttgg	atctaagtaa	aaatagtata	tttttgtca	agtcctctga	ttttcagcat	1680
ctttcttcc	tcaaattgcct	gaatctgtca	ggaaatctca	ttagccaaac	tcttaatggc	1740
agtgaattcc	aaccctttagc	agagctgaga	tattttggact	tctccaacaa	ccggcttgat	1800
ttactccatt	caacagcatt	tgaagagctt	cacaaactgg	aagttctgga	tataagcagt	1860
aatagccatt	atttcaatc	agaaggaatt	actcatatgc	taaactttac	caagaaccta	1920
aaggttctgc	agaaaactgat	gatgaacgac	aatgacatct	cttcctccac	cagcaggacc	1980
atggagagtg	agtctcttag	aactctggaa	ttcagaggaa	atcacttaga	tgttttatgg	2040
agagaaggtg	ataacagata	cttacaatta	ttcaagaatc	tgctaaaatt	agaggaatta	2100
gacatctcta	aaaattccct	aagtttcttgc	ccttctggag	ttttgtatgg	tatgcctcca	2160
aatctaaaga	atctctctt	ggccaaaaat	gggctcaaatt	ctttcagtttgc	gaagaaactc	2220
cagtgtctaa	agaaccttgg	aactttggac	ctcagccaca	accaactgac	caactgtccct	2280
gagagattat	ccaaactgttc	cagaagcctc	aagaatctga	ttcttaagaa	taatcaaatc	2340
aggagtctga	cgaagtattt	tctacaagat	gccttccagt	tgcgatatct	ggatctcagc	2400
tcaaataaaa	tccagatgtat	ccaaaagacc	agcttcccag	aaaatgtcct	caacaatctg	2460
aagatgttgc	ttttgcata	taatcggttt	ctgtgcaccc	gtgatgctgt	gtggtttgc	2520
tggtgggtta	accatacgga	ggtgactatt	ccttacctgg	ccacagatgt	gacttgtgt	2580
gggccaggag	cacacaaggg	ccaaagtgtg	atctccctgg	atctgtacac	ctgtgagttt	2640
gatctgacta	acctgattct	gttctcaattt	tccatatactg	tatctctttt	tctcatgggt	2700
atgatgacag	caagtacacct	ctatttctgg	gatgtgtgtt	atatttacca	tttctgttaag	2760
gccaagataa	aggggtatca	gcgtctaata	tcaccagact	gttgctatga	tgcttttatt	2820
gtgtatgaca	ctaaagaccc	agctgtgacc	gagtgggtt	tggctgagct	ggtggccaaa	2880
ctggaagacc	caagagagaa	acattttat	ttatgtctcg	aggaaaggga	ctggttacca	2940

58182US002.ST25.txt

ggcagccag ttctggaaaa ctttcccag agcatacagc ttagcaaaaa gacagtgtt	3000
gtgatgacag acaagtatgc aaagactgaa aatttaaga tagcattta ctgtcccat	3060
caggagctca tggatgaaaa agtgatgtg attatcttga tatttcttga gaagccctt	3120
cagaagtcca agtcctcca gctccggaaa aggctctgtg ggagttctgt cttgagtgg	3180
ccaacaaacc cgcaagctca cccatacttc tggcagtgtc taaagaacgc cctggccaca	3240
gacaatcatg tggcctatag tcaggtgttc aaggaaacgg tctagccctt cttgcaaaa	3300
cacaactgcc tagttacca aggagaggcc tggctgttta aattgtttc atatatatca	3360
caccaaaagc gtgtttgaa attcttcaag aaatgagatt gccatattt caggggagcc	3420
accaacgtct gtcacaggag ttggaaagat ggggttata taatgcata agtcttctt	3480
cttatctctc tgtgtctcta tttgcacttg agtctctcac ctcaagctcgtt gtaaaagagt	3540
ggcaagtaaa aaacatgggg ctctgattct cctgttaattt tgataattaa atatacacac	3600
aatcatgaca ttgagaagaa ctgcatttct acccttaaaa agtactggta tatacagaaa	3660
tagggttaaa aaaaactcaa gctctctcta tatgagacca aaatgtacta gagtttagtt	3720
agtgaataa aaaaccagtc agctggccgg gcatggtgcc tcattgttgc aatcccagca	3780
cttgggagg ccgaggcagg tggatcacga ggtcaggagt ttgagaccag tctggccaac	3840
atggtaaac cccgtctgta ctaaaaatac aaaaatttcg tggcggttgt ggtgggtgcc	3900
tgtaatccca gctacttggg aggctgaggc aggagaatcg cttgaacccg ggaggtggag	3960
gtggcagtga gccgagatca cgccactgca atgcagcccg ggcaacagag ctagactgtc	4020
tcaaaagaac aaaaaaaaaa aaacacaaaaa aaactcagtc agcttcttaa ccaattgctt	4080
ccgtgtcatc cagggccccca ttctgtcag attgagtgtg ggcaccacac aggtggttgc	4140
tgcttcagtg cttcctgctc ttttccttgc ggcctgcttc tgggttccat agggaaacag	4200
taagaaagaa agacacatcc ttaccataaa tgcataatggt ccacctacaa atagaaaaat	4260
attnaatga tctgcctta tacaaagtga tattctctac cttgataat ttacctgctt	4320
aaatgtttt atctgcactg caaagtactg tatccaaagt aaaatttcct catccaatat	4380
ctttcaaact gtttgttaa ctaatgccat atattgtaa gtatctgcac acttgataca	4440
gcaacgttag atgggtttga tggtaaaccc taaaggagga ctccaagagt gtgtatTTT	4500
ttatagttt atcagagatg acaattttt gaatgcata tataatggatt ctttcattt	4560
tttgctggag gatgggagaa gaaaccaaag tttatagacc ttcacattga gaaagcttca	4620
gtttgaact tcagctatca gattaaaaaa caacagaaag aaccaagaca ttcttaagat	4680
gcctgtactt tcagctgggt ataaattcat gagttcaag attgaaacct gaccaatttg	4740
ctttatTTCA tggaaagatg gatctacaaa ggtgtttgtg ccatttgaa aacagcgtgc	4800

58182US002.ST25.txt

atgtgttcaa gccttagatt ggcgatgtcg tatttcctc acgtgtggca atgccaagg 4860
 ctttacttta cctgtgagta cacactatac gaattatttc caacgtacat ttaatcaata 4920
 agggtcacaa attcccaaatt caatctctgg aataaataga gaggttaatta aattgctgga 4980
 gccaactatt tcacaacttc tgtaagc 5007

<210> 14

<211> 1049

<212> PRT

<213> Homo sapiens

<400> 14

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe
 1 5 10 15

Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys
 20 25 30

Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile
 35 40 45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro
 50 55 60

Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile
 65 70 75 80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe
 85 90 95

Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys
 100 105 110

Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr
 115 120 125

Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln
 130 135 140

Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile
 145 150 155 160

Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile
 165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser
 180 185 190

58182US002.ST25.txt

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro
210 215 220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile
225 230 235 240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro
260 265 270

Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala
275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His
290 295 300

Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp
305 310 315 320

Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu
325 330 335

His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu
340 345 350

Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser
355 360 365

Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu
370 375 380

Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu
385 390 395 400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met
405 410 415

Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys
420 425 430

Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala
435 440 445

58182US002.ST25.txt

Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His
450 455 460

Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys
465 470 475 480

Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln
485 490 495

Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp
500 505 510

Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu
515 520 525

Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu
530 535 540

Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr
545 550 555 560

Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn
565 570 575

Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr
580 585 590

Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile
595 600 605

Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu
610 615 620

Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn
625 630 635 640

Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp
645 650 655

Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly
660 665 670

Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys
675 680 685

Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu
Page 33

58182US002.ST25.txt

690	695	700
Asp Leu Ser His Asn Gln Leu Thr Thr Val Pro Glu Arg Leu Ser Asn		
705	710	715
720		
Cys Ser Arg Ser Leu Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg		
725	730	735
Ser Leu Thr Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu		
740	745	750
Asp Leu Ser Ser Asn Lys Ile Gln Met Ile Gln Lys Thr Ser Phe Pro		
755	760	765
Glu Asn Val Leu Asn Asn Leu Lys Met Leu Leu Leu His His Asn Arg		
770	775	780
Phe Leu Cys Thr Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn His		
785	790	795
800		
Thr Glu Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val Gly		
805	810	815
Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr Thr		
820	825	830
Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Leu Ser Ile Ser		
835	840	845
Val Ser Leu Phe Leu Met Val Met Met Thr Ala Ser His Leu Tyr Phe		
850	855	860
Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly		
865	870	875
880		
Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val		
885	890	895
Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu		
900	905	910
Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu		
915	920	925
Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser		
930	935	940

58182US002.ST25.txt

Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys
 945 950 955 960

Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln
 965 970 975

Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu
 980 985 990

Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys
 995 1000 1005

Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro
 1010 1015 1020

Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His
 1025 1030 1035

Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val
 1040 1045

<210> 15

<211> 3311

<212> DNA

<213> Homo sapiens

<400> 15

ttctgcgctg ctgcaagtta cggaatgaaa aattagaaca acagaaacat ggaaaacatg 60

ttccttcagt cgtcaatgct gacctgcatt ttcctgctaa tatctggttc ctgtgagttt 120

tgcgccgaag aaaatttttc tagaagctat ctttgtatg agaaaaagca aaatgactca 180

gttattgcag agtgcagcaa tcgtcgacta caggaagttc cccaaacggt gggcaaataat 240

gtgacagaac tagacctgtc tgataatttc atcacacaca taacgaatga atcattcaa 300

gggctgcaaa atctcactaa aataaatcta aaccacaacc ccaatgtaca gcaccagaac 360

ggaaatcccg gtatacaatc aaatggcttg aatatcacag acggggcatt cctcaaccta 420

aaaaacctaa gggagttact gcttgaagac aaccagttac cccaaatacc ctctggttt 480

ccagagtctt tgacagaact tagtctaatt caaaaacaata tatacaacat aactaaagag 540

ggcatttcaa gacttataaa cttgaaaaat ctctatttg cctgaaactg ctatTTAAC 600

aaagtttgcg agaaaactaa catagaagat ggagtattt aacgctgac aaatttggag 660

ttgctatcac tatctttcaa ttctcttca cacgtgccac ccaaactgcc aagctcccta 720

cgcAAacttt ttctgagcaa cacccagatc aaatacatta gtgaagaaga tttcaaggga 780

ttgataaaat taacattact agatTTAAGC gggactgtc cgaggtgctt caatGCCCA 840

tttccatgcg tgccttgcg tgggggtgc tcaattaata tagatcgTTT tgctttcaa 900

58182US002.ST25.txt

aacctgaccc	aacttcgata	cctaaacctc	tctagcactt	ccctcaggaa	gattaatgct	960
gcctggttta	aaaatatgcc	tcatctgaag	gtgctggatc	ttgaattcaa	ctatttagtg	1020
ggagaaaatag	cctctggggc	attttaacg	atgctgcccc	gcttagaaat	acttgacttg	1080
tcttttaact	atataaaggg	gagttatcca	cagcatatta	atattccag	aaacttctct	1140
aaacttttgt	ctctacgggc	attgcattta	agaggttatg	tgttccagga	actcagagaa	1200
gatgatttcc	agccctgat	gcagcttcca	aacttatcga	ctatcaactt	gggtattaaat	1260
tttattaagc	aatcgattt	caaacttttc	caaaatttct	ccaatctgga	aattatttac	1320
ttgtcagaaa	acagaatatc	accgttggta	aaagataaccc	ggcagagtta	tgcaaatagt	1380
tcctctttc	aacgtcatat	ccggaaacga	cgctcaacag	atttgagtt	tgacccacat	1440
tcgaactttt	atcatttcac	ccgtccttta	ataaagccac	aatgtgctgc	ttatggaaaa	1500
gccttagatt	taagcctcaa	cagtatttc	ttcattgggc	caaaccatt	tgaaaatctt	1560
cctgacattg	cctgtttaaa	tctgtctgca	aatagcaatg	ctcaagtgtt	aagtggaaact	1620
gaattttcag	ccattcctca	tgtcaaataat	ttggatttga	caaacaatag	actagacttt	1680
gataatgcta	gtgctttac	tgaattgtcc	gacttggaaag	ttctagatct	cagctataat	1740
tcacactatt	tcagaatagc	aggcgtaaca	catcatctag	aatttattca	aaatttcaca	1800
aatctaaaag	ttttaaactt	gagccacaac	aacattata	cttaacaga	taagtataac	1860
ctggaaagca	agtccctgg	agaatttagtt	ttcagtggca	atgccttga	cattttgtgg	1920
aatgatgatg	acaacaggt	tatctccatt	ttcaaaggtc	tcaagaatct	gacacgtctg	1980
gatttatccc	ttaataggt	gaagcacatc	ccaaatgaag	cattccttaa	tttgcagcgc	2040
agtctcactg	aactacat	aaatgataat	atgttaaagt	tttttaactg	gacattactc	2100
cagcagttcc	ctcgctcga	gttgcttgac	ttacgtggaa	acaaactact	cttttaact	2160
gatagcctat	ctgactttac	atctccctt	cggacactgc	tgctgagtca	taacaggatt	2220
tcccacctac	cctctggctt	tctttctgaa	gtcagtagtc	tgaagcacct	cgatttaagt	2280
tccaatctgc	taaaaacaat	caacaaatcc	gcacttgaaa	ctaagaccac	caccaaatta	2340
tctatgttgg	aactacacgg	aaacccctt	gaatgcacct	gtgacattgg	agatttccga	2400
agatggatgg	atgaacatct	gaatgtcaaa	attcccagac	tggtagatgt	catttgtgcc	2460
agtcctgggg	atcaaagagg	gaagagtatt	gtgagtcgg	agctgacaac	ttgtgtttca	2520
gatgtcactg	cagtgatatt	attttcttc	acgttcttta	tcaccaccat	ggttatgttg	2580
gctgccctgg	ctcaccattt	gtttactgg	gatgtttgg	ttatataaa	tgtgtgttta	2640
gctaaggtaa	aaggctacag	gtctcttcc	acatccaaa	cttctatga	tgcttacatt	2700
tcttatgaca	ccaaagatgc	ctctgttact	gactgggtga	taaatgagct	gcgcattaccac	2760.

58182US002.ST25.txt

cttgaagaga gccgagacaa aaacgttctc	ctttgtctag aggagaggga ttgggaccgg	2820
ggattggcca tcatcgacaa cctcatgcag agcatcaacc aaagcaagaa aacagtattt		2880
gttttaacca aaaaatatgc aaaaagctgg aactttaaaa cagctttta cttggcttg		2940
cagaggctaa tggatgagaa catggatgtg attatattta tcctgctgga gccagtgtta		3000
cagcattctc agtattttag gctacggcag cgatctgta agagctccat cctccagtgg		3060
cctgacaacc cgaaggcaga aggcttgtt tggcaaactc tgagaaatgt ggtcttgact		3120
gaaaatgatt cacgtataa caatatgtat gtcgattcca ttaagcaata ctaactgacg		3180
ttaagtcatg atttcgcgcc ataataaaga tgcaaaggaa tgacattct gtattagtt		3240
tctattgcta tgtaacaaat tatccaaaaa cttagtggtt taaaacaaca catttgcgg		3300
cccacagttt t		3311

<210> 16

<211> 1041

<212> PRT

<213> Homo sapiens

<400> 16

Met Glu Asn Met Phe Leu Gln Ser Ser	Met Leu Thr Cys Ile Phe Leu		
1	5	10	15

Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg		
20	25	30

Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu		
35	40	45

Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr		
50	55	60

Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn			
65	70	75	80

Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His		
85	90	95

Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn		
100	105	110

Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg		
115	120	125

Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu		
130	135	140

58182US002.ST25.txt

Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn
145 150 155 160

Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr
165 170 175

Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile
180 185 190

Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu
195 200 205

Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu
210 215 220

Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu
225 230 235 240

Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn
245 250 255

Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly
260 265 270

Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln
275 280 285

Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala
290 295 300

Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe
305 310 315 320

Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu
325 330 335

Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser
340 345 350

Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser
355 360 365

Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu
370 375 380

Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn
385 390 395 400

58182US002.ST25.txt

Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn
405 410 415

Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro
420 425 430

Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser Phe Gln
435 440 445

Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His
450 455 460

Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala
465 470 475 480

Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile
485 490 495

Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu Asn Leu
500 505 510

Ser Ala Asn Ser Asn Ala Gln val Leu Ser Gly Thr Glu Phe Ser Ala
515 520 525

Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu Asp Phe
530 535 540

Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val Leu Asp
545 550 555 560

Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr His His
565 570 575

Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn Leu Ser
580 585 590

His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu Ser Lys
595 600 605

Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile Leu Trp
610 615 620

Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu Lys Asn
625 630 635 640

Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile Pro Asn
Page 39

58182us002.ST25.txt
645 650 655

Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His Ile Asn
660 665 670

Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln Phe Pro
675 680 685

Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe Leu Thr
690 695 700

Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu Leu Ser
705 710 715 720

His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu Val Ser
725 730 735

Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr Ile Asn
740 745 750

Lys Ser Ala Leu Glu Thr Lys Thr Thr Lys Leu Ser Met Leu Glu
755 760 765

Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp Phe Arg
770 775 780

Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu Val Asp
785 790 795 800

Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile Val Ser
805 810 815

Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile Leu Phe
820 825 830

Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala Leu Ala
835 840 845

His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val Cys Leu
850 855 860

Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr Phe Tyr
865 870 875 880

Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr Asp Trp
885 890 895

58182US002.ST25.txt

Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp Lys Asn
900 905 910

Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile
915 920 925

Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr Val Phe
930 935 940

Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe
945 950 955 960

Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val Ile Ile
965 970 975

Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu Arg Leu
980 985 990

Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro
995 1000 1005

Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn Val Val Leu
1010 1015 1020

Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val Asp Ser Ile
1025 1030 1035

Lys Gln Tyr
1040

<210> 17
<211> 3352
<212> DNA
<213> Homo sapiens

<400> 17
aggctggat aaaaatctta cttcctctat tctctgagcc gctgctgcc ctgtggaaag 60
ggacctcgag tgtgaagcat cttccctgt agctgctgtc cagtctgcc gccagaccct 120
ctggagaagc ccctgcccccc cagcatgggt ttctgcccaca gcgccttgca cccgctgtct 180
ctcctggtgtc aggccatcat gctggccatg accctggccc tgggtacctt gcctgccttc 240
ctaccctgtg agctccagcc ccacggcctg gtgaactgca actggctgtt cctgaagtct 300
gtgccccact tctccatggc agcacccgt ggcaatgtca ccagcctttc cttgtcctcc 360
aaccgcatttcc accacctcca tgattctgac tttgcccacc tgcccagcct gcggcatctc 420
aacctcaagt ggaactgccc gccggttggc ctcagcccca tgcaattccc ctgccacatg 480
accatcgagc ccagcacctt cttggctgtg cccaccctgg aagagctaaa cctgagctac 540

58182US002.ST25.txt

aacaacatca	tgactgtgcc	tgcgctgccc	aaatccctca	tatccctgtc	cctcagccat	600
accaacatcc	tgatgctaga	ctctgccagc	ctcgccggcc	tgcattccct	gcgccttcta	660
ttcatggacg	gcaactgtta	ttacaagaac	ccctgcaggc	aggactgga	ggtggccccg	720
ggtgccctcc	ttggcctggg	caacctcacc	cacctgtcac	tcaagtacaa	caacctcact	780
gtggtgcccc	gcaacctgcc	ttccagcctg	gagtatctgc	tgttgtccta	caaccgcac	840
gtcaaactgg	cgcctgagga	cctggccaat	ctgaccgccc	tgcgtgtgct	cgatgtggc	900
ggaaattgcc	gccgctgcga	ccacgctccc	aaccctgca	tggagtgccc	tcgtcacttc	960
ccccagctac	atcccgatac	cttcagccac	ctgagccgtc	ttgaaggcct	ggtgttgaag	1020
gacagttctc	tctcctggct	gaatgccagt	tggttccgtg	ggctgggaaa	cctccgagtg	1080
ctggacctga	gtgagaactt	cctctacaaa	tgcattacta	aaaccaaggc	cttccagggc	1140
ctaacacagc	tgcgcaagct	taacctgtcc	ttcaattacc	aaaagagggt	gtcctttgcc	1200
cacctgtctc	tggcccttc	cttcgggagc	ctggtcgccc	tgaaggagct	ggacatgcac	1260
ggcatcttct	tccgctcact	cgatgagacc	acgctccggc	cactggccc	cctgcccatt	1320
ctccagactc	tgcgtctgca	gatgaacttc	atcaaccagg	cccagctcgg	catcttcagg	1380
gcctccctg	gcctgcgcta	cgtggacctg	tcggacaacc	gcatcagcgg	agcttcggag	1440
ctgacagcca	ccatggggga	ggcagatgga	ggggagaagg	tctggctgca	gcctggggac	1500
cttgctccgg	ccccagtgga	cactcccagc	tctgaagact	tcaggccaa	ctgcagcacc	1560
ctcaacttca	ccttggatct	gtcacggaac	aacctggta	ccgtgcagcc	ggagatgttt	1620
gcccgactct	cgcacctgca	gtgcctgcgc	ctgagccaca	actgcatttc	gcaggcagtc	1680
aatggctccc	agttcctgcc	gctgaccggt	ctgcaggtgc	tagacctgtc	ccgcaataag	1740
ctggacctct	accacgagca	ctcattcag	gagctaccgc	gactggaggc	cctggacctc	1800
agctacaaca	gccagccctt	tggcatgca	ggcgtgggcc	acaacttcag	ttcgtggct	1860
cacctgcgca	ccctgcgcca	cctcagcctg	gcccacaaca	acatccacag	ccaagtgtcc	1920
cagcagctct	gcagtacgtc	gctgcgggccc	ctggacttca	gcggcaatgc	actggccat	1980
atgtggcccg	agggagacct	ctatctgcac	ttcttccaag	gcctgagcgg	tttgatctgg	2040
ctggacttgt	cccagaaccg	cctgcacacc	ctcctgcccc	aaaccctgca	caacctcccc	2100
aagagcctac	aggtgctgca	tctccgtac	aattacctgg	cttctttaa	gtggtggagc	2160
ctccacttcc	tgcccuaact	ggaagtccctc	gacctggcag	gaaaccggct	gaaggccctg	2220
accaatggca	gcctgcctgc	tggcacccgg	ctccggaggc	tggatgtcag	ctgcaacagc	2280
atcagcttcg	tggcccccgg	cttctttcc	aaggccaagg	agctgcgaga	gctcaacatt	2340
agcgccaaacg	ccctcaagac	agtggaccac	tcctggtttgc	ggccctggc	gagtgcctg	2400

58182US002.ST25.txt

caaatactag	atgtaaagcgc	caaccctctg	cactgcgcct	gtggggcgcc	ctttatggac	2460
ttcctgctgg	agggcaggc	tgcgcgtccc	ggtctgccc	gccgggtgaa	gtgtggcagt	2520
ccggggccagc	tccaggccct	cagcatctt	gcacaggacc	tgcgcctctg	cctggatgag	2580
gccctctcct	gggactgttt	cgcgcctctg	ctgctggctg	tggctctggg	cctgggtgtg	2640
cccatgctgc	atcacctctg	tggctgggac	ctctggtaact	gcttccacct	gtgcctggcc	2700
tggcttcct	ggcggggcg	gcaaagtggg	cgagatgagg	atgcctgccc	ctacgatgcc	2760
ttcgtggtct	tcgacaaaac	gcagagcgc	gtggcagact	gggtgtacaa	cgagttcgg	2820
gggcagctgg	aggagtgcgc	tggcgctgg	gcactccgc	tgtgcctgga	ggaacgcgac	2880
tggctgcctg	gcaaaaccct	cttgagaac	ctgtgggcct	cggcttatgg	cagccgcaag	2940
acgctgttg	tgctggccca	cacggaccgg	gtcagtggtc	tctgcgcgc	cagcttcctg	3000
ctggcccagc	agcgcctgct	ggaggaccgc	aaggacgtcg	tggtgctgg	gatcctgagc	3060
cctgacggcc	gccgctcccg	ctacgtgcgg	ctgcgcgcagc	gcctctgccc	ccagagtgtc	3120
ctcccttggc	cccaccagcc	cagtggtcag	cgcagttct	gggcccagct	gggcatggcc	3180
ctgaccaggg	acaaccacca	cttctataac	cgaaacttct	gccagggacc	cacggccaa	3240
tagccgtgag	ccggaatcct	gcacggtgcc	acctccacac	tcacctcacc	tctgcctgcc	3300
tggtctgacc	ctccccctgct	cgccctccctc	accccacacc	tgacacagag	ca	3352

<210> 18

<211> 1032

<212> PRT

<213> Homo sapiens

<400> 18

Met	Gly	Phe	Cys	Arg	Ser	Ala	Leu	His	Pro	Leu	Ser	Leu	Leu	Val	Gln
1						5				10				15	

Ala	Ile	Met	Leu	Ala	Met	Thr	Leu	Ala	Leu	Gly	Thr	Leu	Pro	Ala	Phe
		20					25					30			

Leu	Pro	Cys	Glu	Leu	Gln	Pro	His	Gly	Leu	Val	Asn	Cys	Asn	Trp	Leu
		35				40					45				

Phe	Leu	Lys	Ser	Val	Pro	His	Phe	Ser	Met	Ala	Ala	Pro	Arg	Gly	Asn
				50			55				60				

Val	Thr	Ser	Leu	Ser	Leu	Ser	Ser	Asn	Arg	Ile	His	His	Leu	His	Asp
			65			70			75				80		

Ser	Asp	Phe	Ala	His	Leu	Pro	Ser	Leu	Arg	His	Leu	Asn	Leu	Lys	Trp
					85			90				95			

58182US002.ST25.txt

Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met
100 105 110

Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu
115 120 125

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser
130 135 140

Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser
145 150 155 160

Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr
195 200 205

Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr
210 215 220

Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe
260 265 270

Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe
290 295 300

Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu
305 310 315 320

Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala
340 345 350

58182US002.ST25.txt

His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu
355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu
370 375 380

Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu
420 425 430

Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu
435 440 445

Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu
450 455 460

Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser
465 470 475 480

Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser
485 490 495

His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val
500 505 510

Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu
515 520 525

Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu
530 535 540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly
545 550 555 560

Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr
565 570 575

Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser
580 585 590

Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn
Page 45

595 600 58182US002.ST25.txt
 605

Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe
610 615 620

Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu
625 630 635 640

His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln
645 650 655

Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser
660 665 670

Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Arg
675 680 685

Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg
690 695 700

Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe
705 710 715 720

Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala
725 730 735

Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu
740 745 750

Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala
755 760 765

Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu
770 775 780

Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser
785 790 795 800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp
805 810 815

Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val
820 825 830

Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His
835 840 845

58182US002.ST25.txt

Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp
 850 855 860

Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln
 865 870 875 880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu
 885 890 895

Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp
 900 905 910

Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr
 915 920 925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser
 930 935 940

Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu
 945 950 955 960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg
 965 970 975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val
 980 985 990

Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln
 995 1000 1005

Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg
 1010 1015 1020

Asn Phe Cys Gln Gly Pro Thr Ala Glu
 1025 1030

<210> 19

<211> 3002

<212> DNA

<213> Homo sapiens

<400> 19

gtggcttggc attcaactggc aggtttcaga catttagatc tttcttttaa tgactaacac 60

catgcctatc tgtggagaag ctggcaacat gtcacacctg gaaattgttt ttcaacatta 120

atactattat ttggcagtaa tccagattgc tttgccacc aacctgaaga catatagagg 180

cagaaggaca ggaataattc tatttgttgc ctgtttgaa acttccatct gtaaggctat 240

caaaaggaga tgtgagagag ggtattgagt ctggcctgac aatgcagttc tttaaacaaa 300

58182US002.ST25.txt

ggtccattat gcttctcctc	tctgagaatc ctgacttacc tcaacaacgg agacatggca	360
cagtagccag cttggagact ttcagccaa tgctctgaga tcaagtcgaa gacccaatat	420	
acagggttt gagctcatct tcatttcattca tatgagggaaa taagtggtaa aatccttgaa	480	
aatacaatga gactcatcg aaacatttac atattttgtt gtattgtt gacagcagag	540	
ggtgatgctc cagagctgcc agaagaaagg gaactgtga ccaactgctc caacatgtct	600	
ctaagaaagg ttcccgcaga cttgacccca gccacaacga cactggattt atcctataac	660	
ctccttttc aactccagag tttagattt cattctgtct ccaaactgag agtttgatt	720	
ctatgccata acagaattca acagctggat ctcaaaacctt ttgaattcaa caaggagttt	780	
agatatttag atttgtctaa taacagactg aagagtgtt cttggatttt actggcaggt	840	
ctcaggtatt tagatcttc tttaatgac ttgacacca tgccatctg tgaggaagct	900	
ggcaacatgt cacacctgga aatccttaggt ttgagtgggg caaaaataca aaaatcagat	960	
ttccagaaaa ttgctcatct gcatctaaat actgtcttct taggattcag aactcttcct	1020	
cattatgaag aaggtgcct gcccattta aacacaacaa aactgcacat tgtttacca	1080	
atggacacaa atttctgggt tctttgcgt gatggaatca agacttcaaa aatattagaa	1140	
atgacaaata tagatggcaa aagccattt gtaagttatg aaatgcaacg aaatcttagt	1200	
tttagaaaatg ctaagacatc ggttctattt cttaataaag ttgattact ctggacgac	1260	
ctttcctta tcttacaatt tggatggcat acatcgtgg aacactttca gatccgaaat	1320	
gtgacttttgcgtt gtggtaaggc ttatcttgcac cacaattcat ttgactactc aaatactgtt	1380	
atgagaacta taaaatttggaa gcatgtacat tttagtgcgtt ttacattca acaggataaa	1440	
atctatttgc ttttgcacaa aatggacata gaaaacctga caatatcaaa tgcacaaatg	1500	
ccacacatgc ttttccgaa ttatcctacg aaattccaaat atttaaattt tgccaataat	1560	
atcttaacag acgagttgtt taaaagaact atccaaactgc ctcaacttgc aactctcatt	1620	
ttgaatggca ataaacttggaa gacactttct ttagtaagtt gctttgttcaaa caacacaccc	1680	
ttggaaacttgcgtt tggatctgag tcaaaatcta ttacaacata aaaatgtga aaattgctca	1740	
tggccagaaaa ctgtggtcaa tatgaatctg tcatacataaattgtctga ttctgtcttc	1800	
aggtgcttgc ccaaaagtat tcaaatactt gacctaaata ataaccaaataat ccaaactgtt	1860	
cctaaagaga ctattcatct gatggcctta cgagaactaa atattgcatt taattttcta	1920	
actgatctcc ctggatgcag tcatttcagt agactttcag ttctgaacat tgaaatgttac	1980	
ttcattctca gcccattctt ggattttgtt cagagctgcc aggaagttaa aactctaaat	2040	
gcggaaagaa atccattccg gtgtacctgtt gaattaaaaa atttcattca gcttgaaaca	2100	
tattcagagg tcatgtatgtt tggatggtca gattcataca cctgtgaata ccctttaaac	2160	

58182US002.ST25.txt

ctaaaggaa ttaggtaaa agacgttcat	ctccacgaat tatcttgcaa cacagctctg	2220
ttgattgtca ccattgtggt tattatgcta	gttctgggt tggctgtggc cttctgctgt	2280
ctccacttg atctgccctg gtatctcagg atgcttaggtc	aatgcacaca aacatggcac	2340
agggttagga aaacaaccca agaacaactc	aagagaaatg tccgattcca cgcatattatt	2400
tcatacagt aacatgattc tctgtgggtg	aagaatgaat tgatccccaa tctagagaag	2460
gaagatggtt ctatcttgc	ttgcctttat gaaagctact ttgaccctgg caaaaggcatt	2520
agtaaaaata ttgttaagctt cattgagaaa	agctataagt ccattttgtt tttgtctccc	2580
aactttgtcc agaatgagtg gtgccattat	gaattttact ttgcccacca caatctcttc	2640
cataaaaatt ctgatcatat aattcttatac	ttactggaac ccattccatt ctattgcatt	2700
cccaccaggat atcataaact gaaagctctc	ctggaaaaaaa aagcataactt ggaatggccc	2760
aaggataggc gtaaatgtgg gctttctgg	gcaaacccttc gagctgctat taatgttaat	2820
gtattagcca ccagagaaat gtatgaactg	cagacattca cagagtaaa tgaagagtct	2880
cgaggttcta caatctctct	gatgagaaca gattgtctat aaaatcccac agtccttggg	2940
aagttgggga ccacatacac tttttttttt tacattgata	caacctttat gatggcaatt	3000
tg		3002

<210> 20

<211> 811

<212> PRT

<213> Homo sapiens

<400> 20

Met Arg Leu Ile Arg Asn Ile Tyr Ile Phe Cys Ser Ile Val Met Thr			
1	5	10	15

Ala Glu Gly Asp Ala Pro Glu Leu Pro Glu Glu Arg Glu Leu Met Thr		
20	25	30

Asn Cys Ser Asn Met Ser Leu Arg Lys Val Pro Ala Asp Leu Thr Pro		
35	40	45

Ala Thr Thr Thr Leu Asp Leu Ser Tyr Asn Leu Leu Phe Gln Leu Gln		
50	55	60

Ser Ser Asp Phe His Ser Val Ser Lys Leu Arg Val Leu Ile Leu Cys			
65	70	75	80

His Asn Arg Ile Gln Gln Leu Asp Leu Lys Thr Phe Glu Phe Asn Lys		
85	90	95

Glu Leu Arg Tyr Leu Asp Leu Ser Asn Asn Arg Leu Lys Ser Val Thr	
Page 49	

58182US002.ST25.txt
100 105 110
Trp Tyr Leu Leu Ala Gly Leu Arg Tyr Leu Asp Leu Ser Phe Asn Asp
115 120 125

Phe Asp Thr Met Pro Ile Cys Glu Glu Ala Gly Asn Met Ser His Leu
130 135 140

Glu Ile Leu Gly Leu Ser Gly Ala Lys Ile Gln Lys Ser Asp Phe Gln
145 150 155 160

Lys Ile Ala His Leu His Leu Asn Thr Val Phe Leu Gly Phe Arg Thr
165 170 175

Leu Pro His Tyr Glu Glu Gly Ser Leu Pro Ile Leu Asn Thr Thr Lys
180 185 190

Leu His Ile Val Leu Pro Met Asp Thr Asn Phe Trp Val Leu Leu Arg
195 200 205

Asp Gly Ile Lys Thr Ser Lys Ile Leu Glu Met Thr Asn Ile Asp Gly
210 215 220

Lys Ser Gln Phe Val Ser Tyr Glu Met Gln Arg Asn Leu Ser Leu Glu
225 230 235 240

Asn Ala Lys Thr Ser Val Leu Leu Leu Asn Lys Val Asp Leu Leu Trp
245 250 255

Asp Asp Leu Phe Leu Ile Leu Gln Phe Val Trp His Thr Ser Val Glu
260 265 270

His Phe Gln Ile Arg Asn Val Thr Phe Gly Gly Lys Ala Tyr Leu Asp
275 280 285

His Asn Ser Phe Asp Tyr Ser Asn Thr Val Met Arg Thr Ile Lys Leu
290 295 300

Glu His Val His Phe Arg Val Phe Tyr Ile Gln Gln Asp Lys Ile Tyr
305 310 315 320

Leu Leu Leu Thr Lys Met Asp Ile Glu Asn Leu Thr Ile Ser Asn Ala
325 330 335

Gln Met Pro His Met Leu Phe Pro Asn Tyr Pro Thr Lys Phe Gln Tyr
340 345 350

58182US002.ST25.txt

Leu Asn Phe Ala Asn Asn Ile Leu Thr Asp Glu Leu Phe Lys Arg Thr
355 360 365

Ile Gln Leu Pro His Leu Lys Thr Leu Ile Leu Asn Gly Asn Lys Leu
370 375 380

Glu Thr Leu Ser Leu Val Ser Cys Phe Ala Asn Asn Thr Pro Leu Glu
385 390 395 400

His Leu Asp Leu Ser Gln Asn Leu Leu Gln His Lys Asn Asp Glu Asn
405 410 415

Cys Ser Trp Pro Glu Thr Val Val Asn Met Asn Leu Ser Tyr Asn Lys
420 425 430

Leu Ser Asp Ser Val Phe Arg Cys Leu Pro Lys Ser Ile Gln Ile Leu
435 440 445

Asp Leu Asn Asn Asn Gln Ile Gln Thr Val Pro Lys Glu Thr Ile His
450 455 460

Leu Met Ala Leu Arg Glu Leu Asn Ile Ala Phe Asn Phe Leu Thr Asp
465 470 475 480

Leu Pro Gly Cys Ser His Phe Ser Arg Leu Ser Val Leu Asn Ile Glu
485 490 495

Met Asn Phe Ile Leu Ser Pro Ser Leu Asp Phe Val Gln Ser Cys Gln
500 505 510

Glu Val Lys Thr Leu Asn Ala Gly Arg Asn Pro Phe Arg Cys Thr Cys
515 520 525

Glu Leu Lys Asn Phe Ile Gln Leu Glu Thr Tyr Ser Glu Val Met Met
530 535 540

Val Gly Trp Ser Asp Ser Tyr Thr Cys Glu Tyr Pro Leu Asn Leu Arg
545 550 555 560

Gly Ile Arg Leu Lys Asp Val His Leu His Glu Leu Ser Cys Asn Thr
565 570 575

Ala Leu Leu Ile Val Thr Ile Val Val Ile Met Leu Val Leu Gly Leu
580 585 590

Ala Val Ala Phe Cys Cys Leu His Phe Asp Leu Pro Trp Tyr Leu Arg
595 600 605

58182US002.ST25.txt

Met Leu Gly Gln Cys Thr Gln Thr Trp His Arg Val Arg Lys Thr Thr
 610 615 620

Gln Glu Gln Leu Lys Arg Asn Val Arg Phe His Ala Phe Ile Ser Tyr
 625 630 635 640

Ser Glu His Asp Ser Leu Trp Val Lys Asn Glu Leu Ile Pro Asn Leu
 645 650 655

Glu Lys Glu Asp Gly Ser Ile Leu Ile Cys Leu Tyr Glu Ser Tyr Phe
 660 665 670

Asp Pro Gly Lys Ser Ile Ser Glu Asn Ile Val Ser Phe Ile Glu Lys
 675 680 685

Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro Asn Phe Val Gln Asn Glu
 690 695 700

Trp Cys His Tyr Glu Phe Tyr Phe Ala His His Asn Leu Phe His Glu
 705 710 715 720

Asn Ser Asp His Ile Ile Leu Ile Leu Leu Glu Pro Ile Pro Phe Tyr
 725 730 735

Cys Ile Pro Thr Arg Tyr His Lys Leu Lys Ala Leu Leu Glu Lys Lys
 740 745 750

Ala Tyr Leu Glu Trp Pro Lys Asp Arg Arg Lys Cys Gly Leu Phe Trp
 755 760 765

Ala Asn Leu Arg Ala Ala Ile Asn Val Asn Val Leu Ala Thr Arg Glu
 770 775 780

Met Tyr Glu Leu Gln Thr Phe Thr Glu Leu Asn Glu Glu Ser Arg Gly
 785 790 795 800

Ser Thr Ile Ser Leu Met Arg Thr Asp Cys Leu
 805 810

<210> 21
 <211> 215
 <212> DNA
 <213> Homo sapiens

<400> 21
 aaaaacaaaa catttgagaa acacggctct aaactcatgt aaagagtgc tgaaggaaag 60
 caaaaacaga aatggaaagt ggcccagaag cattaagaaa gtggaaatca gtatgttccc 120

58182US002.ST25.txt

tat~~ttaaggc~~ atttgcagga agcaaggcct tcagagaacc tagagccaa gtttcagagt 180
cacccatctc agcaagccca gaagtatctg caata 215

<210> 22
<211> 36
<212> DNA
<213> Artificial

<220>
<223> 5' primer for human IFN-alpha promoter

<400> 22
acgagatcta agcttaaaac aaaacatttg agaaac 36

<210> 23
<211> 28
<212> DNA
<213> Artificial

<220>
<223> 3' primer for human IFN-alpha promoter

<400> 23
acgagatcta gatattgcag atacttct 28